Pilot Study  
Examining Oncolytic Poliovirus Bioactivity in Tumor Tissue after 
Intratumoral  Administration  of PVSRIPO  in Women  with Invasive  Breast 
Cancer  
 
 
 
 
Sponsor:  PI and Istari  Oncology,  Inc. (Istari  Oncology, 
Inc. is the IND Sponsor – Signatory, Darell  
Bigner,  MD, PhD)  
Funding  Source:  DoD grant  W81XWH -16-1-0354  
(Smita  Nair,  PI) 
Protocol  Source:  PI and Duke  Cancer  Institute  
Duke  IRB#:  Pro00085352  
IND#:  14,735  
 
Principal  Investigator  
E. Shelley  Hwang,  MD, MPH  
 
Sub-Investigator(s) 
Jeremy Force, MD 
Lars Grimm, MD 
Smita Nair, PhD  
Matthias  Gromeier,  MD 
Darell  D Bigner,  MD, PhD (Istari  signatory  for IND) 
 
Pathologists  
Edgardo  Castellar,  MD, PhD 
Roger McLendon, MD  
 
Statistician  
James  Herndon  II, PhD 
 
Regulatory  
Alli Bosquet  
 
Original  version:  09/08/17   
Updated:  10/09/17   
 12/19/17  
 01/29/18  
 03/12/18  
 06/29/18  
 08/27/18  
 07/15/19  
 09/16/19  
 08/12/21  Change  primary  regulatory  contact  on title 
 
 
 
PT-PhIDEE  v04.30.14  
  page.  Clarification  that any subjects who  do 
not have evaluable tumor tissue from both 
the pre-treatment  biopsy  and post-treatment 
surgery will be replaced. (Sections 5.3, 5.4, 
5.6, 15) This change is meant to allow 
replacement  of subjects  who have  an active 
viral infection while on study, which would  
impact  treatment  related  analysis  and the 
primary objective of the study.  
 
  
1 TABLE  OF CONTENTS  
1 TABLE  OF CONTENTS  ................................ ................................ ................................ ...... 2 
2 LIST OF FIGURES  ................................ ................................ ................................ ............  4 
3 LIST OF TABLES  ................................ ................................ ................................ ..............  4 
4 LIST OF  ABBREVIATIONS  ................................ ................................ ...............................  5 
5 PROTOCOL  SYNOPSIS  AND  RESEARCH  SUMMARY  ................................ ...................  7 
Purpose  ................................ ................................ ................................ .......................  7 
Background  and Significance  ................................ ................................ ......................  7 
Design  and Procedure  ................................ ................................ ................................ .. 8 
Selection  of Subjects  ................................ ................................ ................................ ... 9 
Duration  of Study  ................................ ................................ ................................ ....... 10 
Data  Analysis  and Statistical  Considerations  ................................ .............................  11 
6 STUDY  SCHEMA  ................................ ................................ ................................ ............  11 
7 BACKGROUND  AND  SIGNIFICANCE  ................................ ................................ .............  12 
Study  Disease  ................................ ................................ ................................ ...........  12 
Study  Agent  ................................ ................................ ................................ ...............  13 
7.2.1  Pre-Clinical  Experience  ................................ ................................ .......................  13 
7.2.2  Clinical  Experience  ................................ ................................ ..............................  17 
Study  Purpose  and Rationale  ................................ ................................ .....................  18 
8 OBJECTIVES  AND  ENDPOINTS  ................................ ................................ ....................  19 
9 INVESTIGATIONAL  PLAN  ................................ ................................ ..............................  19 
Study  Design  ................................ ................................ ................................ .............  19 
Safety  Considerations  ................................ ................................ ................................  20 
9.2.1  Surgical  Complications  ................................ ................................ .........................  20 
9.2.2  Anesthesia  ................................ ................................ ................................ ..........  20 
9.2.3  Poliomyelitis  ................................ ................................ ................................ ........  20 
9.2.4  Virus  Recombination  and Mutation  ................................ ................................ ...... 20 
9.2.5  Long -Term  Sequelae  of Virus  Injection  ................................ ...............................  21 
9.2.6  Risks  of Phlebotomy ................................ ................................ ............................  21 
9.2.7  Risks  to Household  Contacts  of Study  Subjects  ................................ ..................  21 
9.2.8  Unacceptable  Toxicities  ................................ ................................ .......................  22 
Rationale  for Selection  of Dose,  Regimen,  and Treatment  Duration  ..........................  22 
Rationale  for Corre lative  Studies  ................................ ................................ ...............  23 

 
 Early  Study  Termination ................................ ................................ .............................  23 
10 STUDY  DRUG  ................................ ................................ ................................ ..............  23 
Names,  Classification,  and Mechanism  of Action  ................................ ....................  23 
Supply,  Receipt,  and Storage  ................................ ................................ ..................  23 
Dispensing  and Preparation  ................................ ................................ ...................  23 
Compliance  and Accountability  ................................ ................................ ...............  24 
Disposal  and Destruction  ................................ ................................ .........................  25 
11 SUBJECT  ELIGIBILITY  ................................ ................................ ................................ . 25 
Inclusion  and Exclusion  Criteria  ................................ ................................ ..............  25 
12 SCREENING  AND  ON-STUDY  TESTS  AND  PROCEDURES  ................................ ..... 25 
Pre-treatment  Period  ................................ ................................ ..............................  27 
Treatment  Period  ................................ ................................ ................................ .... 28 
End of Treatment  ................................ ................................ ................................ .... 28 
Follow -up Period  ................................ ................................ ................................ ..... 28 
End of Study  ................................ ................................ ................................ ...........  28 
Early  Withdrawal  of Subject(s)  ................................ ................................ ................  28 
12.6.1  Criteria  for Early  Withdrawal  ................................ ................................ ............  28 
13 SAFETY  MONITORING  AND  REPORTING  ................................ ................................ . 29 
Adverse  Events  ................................ ................................ ................................ ...... 29 
Reporting  of Serious  Adverse  Events  ................................ ................................ ..... 29 
Safety  Oversight Committee  ................................ ................................ ...................  30 
External  Data  and Safety  Monitoring  ................................ ................................ ...... 30 
14 QUALITY  CONTROL  AND  QUALITY  ASSURANCE  ................................ ....................  31 
Monitoring  ................................ ................................ ................................ ...............  31 
Audits  ................................ ................................ ................................ .....................  32 
Data  Management  and Processing  ................................ ................................ ........  32 
14.3.1  Case  Report  Forms  (CRFs)  ................................ ................................ ..............  32 
14.3.2  Data  Management  Procedures  and Data  Verification  ................................ ...... 32 
14.3.3  Study Closure  ................................ ................................ ................................ .. 33 
15 STATISTICAL  METHODS  AND  DATA  ANALYSIS  ................................ .......................  33 
16 ADMINISTRATIVE  AND  ETHICAL  CONSIDERATIONS  ................................ ................  34 
Regulatory  and Ethical  Compliance  ................................ ................................ .........  34 
DUHS  Institutional  Review  Board  and DCI Cancer  Protocol  Committee  ................  34 
Informed  Consent  ................................ ................................ ................................ ... 34 

 
 Study Documentation  ................................ ................................ .............................  35 
Privacy,  Confidentiality,  and Data  Storage  ................................ .............................  35 
Data  and Safety  Monitoring  ................................ ................................ ....................  36 
Protocol  Amendments  ................................ ................................ ............................  36 
Records  Retention  ................................ ................................ ................................ .. 36 
17 REFERENCES  ................................ ................................ ................................ .............  36 
 
 
2 LIST  OF FIGURES  
Figure  1. Study  Schema  PVSRIPO  for Invasive  Breast  Cancer  ................................ .............  11 
Figure  2. Breast  Cancer  Susceptibility  to PVSRIPO  ................................ ..............................  14 
Figure 3. Immunohistochemistry for the PV Receptor (CD155) in 19 Triple -Negative Breast 
Cancer  Cases  ................................ ................................ ................................ ........................  14 
Figure  4. PVSRIPO  Cytotoxicity  in Breast  Cancer  Cell Lines  ................................ ................  15 
Figure  5. Infection  and Activation  of Dendritic  Cells  (DCs)  by PVSRIPO  ...............................  16 
Figure 6. PVSRIPO -Induced Oncolysate Causes DC Activation in a Virus Dependent  
Fashion.  ................................ ................................ ................................ ................................ . 17 
3 LIST  OF TABLES  
Table  1. Screening  and On-Study  Tests  and Procedures  ................................ ......................  26 

 
 4 LIST  OF ABBREVIATIONS  
 
AE; adverse  event  
ANC;  absolute  neutrophil  count 
APC; antigen present cells  
BCRP;  Breast  Cancer  Research  Program 
CBC; complete blood count  
CBER;  Center  for Biologics  Evaluation  and Research 
CEA; carcinoembryonic antigen  
CMP; complete metabolic panel 
CNS; central nervous system 
CPC;  Cancer  Protocol  Committee 
CRF; case report form  
CTC;  Common  Toxicity  Criteria  
DAMP;  damage -associated  molecular  pattern 
DC; dendritic cell  
DCI; Duke Cancer Institute 
DoD;  Department  of Defense  
DUHS;  Duke  University  Health  System 
ECG; electrocardiogram  
eCTD;  electronic  common  technical  document  
eIF; eukaryotic  initiation  factorELISA;  enzyme -linked  immunosorbent  assay 
ER; estrogen receptor  
E:T; effector  to target ratio 
FDA; Food and Drug Administration 
FFPE;  Formalin -fixed,  Paraffin -embedded 
H&E; hematoxylin and eosin  
HER2;  human  epidermal  growth  factor  receptor 
HIV; human immunodeficiency virus  
HRPO;  Human  Resear ch Protections  Office 
HRV2; human rhinovirus type 2  
HSA;  human  serum  albumin  
ICS; Investigational  Chemotherapy  Services 
IHC; immunohistochemistry  
IND; investigational new drug  
IRB; Institutional Review Board 
IRES;  internal  ribosomal  entry  site 
IT; informat ion technology  
IV; intravenous 
MMG;  mammogram  
MRI;  magnetic  resonance  imaging 
MOI; multiplicity of Infection  
NCI; National  Cancer  Institute 
NHP; non -human primate  
OARC;  Office  of Audit,  Risk,  and Compliance 
OncPV; Oncolytic Poliovirus  
 
 OR; operating  roomPAMP;  pathogen -associated  molecular  pattern 
PD-L1; programmed death ligand 1  
PET;  positron  emission  tomography 
PFS; progression free survival  
PO; by mouth  (latin  term per os) 
PR; proges terone receptor  
PRTBTC;  Preston  Robert  Tisch  Brain  Tumor  Center 
PT; prothrombin time  
PTT; partial thromboplastin time 
PV1S;  poliovirus  serotype  1 (SABIN) 
PVSRIPO;  Polio/Rhinovirus  Recombinant 
RIO; Research Integrity Office  
RNA;  ribonucleic  acid 
SAE;  serious  adverse  event  
SGOT;  serum  glutamic -oxaloacetic  transaminase 
SOC; standard of care  
SOP;  standard  operating  procedure 
TCID;  tissue  culture  infectious  dose 
TIL; tumor infiltrating lymphocytes 
TNBC;  triple  negative  breast  cancer 
ULN: upper limit of nor mal 
WHO;  World  Health Organization  
 
 5 PROTOCOL  SYNOPSIS  AND  RESEARCH  SUMMARY  
Purpose  
To examine oncolytic poliovirus (OncPV) bioactivity in tumor tissue after intratumoral 
administration  of PVSRIPO  (Polio/Rhinovirus  Recombinant)  in women  with invasive  breast 
cancer.  
 
Objectives  (Exploratory) : 
To investigate PVSRIPO -mediated inflammation and immunity in women with stage II -IV 
invasive breast cancer.  
1. Primary Exploratory Objective : To describe the change in the amount of tumor 
infiltrating  immune  cells in tumor  tissue  pre- and post-injection  of PVSRIPO  by H&E 
(Hemotoxylin and Eosin).  
2. Other  Exploratory  Objectives : 
a. To examine  tumor  tissue  pre- and post-injection  of PVSRIPO  for inflammatory 
and immune signatures using arrays, CD155 expression by 
immunohistochemistry (IHC), immune cell infiltrate by IHC and tumor 
infiltrating immune cells using flow cytometry (post -injection only).  
b. To examine blood for inflammatory and immune sign ature using arrays, 
immune  cell composition  (antigen  presenting  cells,  B cells and T cells),  T cell 
activation  by flow cytometry  and B cell activation  by ELISA  and peptide  arrays. 
Blood will be collected on day -7 (range day -7 to -10, before polio vaccine  
booster), day 0 (before PVSRIPO injection), day 2 (range day 1 to 2 after 
PVSRIPO), day 14 (range day 10 to 20, after PVSRIPO before surgery) and 
in follow -up at months 1 (± 10 days) and 6 (± 1 month) post -PVSRIPO.  
 
Hypothesis  
Administration of oncolytic poliovirus, PVSRIPO, in the tumor causes inflammation, which 
stimulates innate and adaptive immune activation, in invasive breast cancer.  
 
Background  and Significance  
Breast cancer is the most common cancer in women in the United States, with an estimated  
246,660  new diagnoses  in 2016,  and is the second  leading  cause  of cancer  death  in 
women,  with an estimated  40,450  women  in the United  States  dying  from the disease  in 
2016  (1). Breast  cancer  is a heterogeneous  disease  comprising  several  molecular  
subtypes, based on receptor status, specifically the estrogen receptor (ER), progesterone 
receptor  (PR),  and human  epidermal  growth  factor  2-neu (HER2)  receptor.  These receptors  
are both prognostic  but also predictive  of response  to targeted  therapy.  
 
Triple Negative Breast Cancer or TNBC (negative for ER, PR, and HER2) represents 15 - 
20% of all breast tumors and has the poorest prognosis, with an earlier  age of diagnosis, 
higher rate of local recurrence and distant metastases, and an elevated 5 -yr mortality rate 
compared  to ER positive  cancers  (Breast  Cancer  Facts  and Figures,  2015 -2016,  American 
Cancer Society). Therapies that stimulate durable systemic immunity and selectively 
eliminate malignant cells will be critical for extending survival and reducing risk of 
recurrence  in women  with breast  cancer.  In several  phase  I trials  targeting  the immune  

 
 checkpoint PD -1/PD -L1, cancer immunotherapy  has been shown to demonstrate some 
promise in TNBC by showing objective response rates in the metastatic setting.  
 
PVSRIPO is a recombinant polio:rhinovirus chimera, engineered to eliminate neuronal 
competence  and is devoid  of neuropathogenicity  upon  inoculation  in primates  and humans. 
PVSRIPO specifically targets and destroys tumor cells and initiates innate and adaptive 
immune  events  in the host.  PVSRIPO  has demonstrated  promise  in a phase  I study  at Duke 
University  in patient s with recurrent  WHO  Grade  4 malignant glioma and is  currently  being 
investigated in a Phase 2 trial in recurrent WHO Grade 4 malignant glioma. A single, 
intratumoral infusion  of PVSRIPO  has been shown to result in  durable tumor regression in 
select patien ts with malignant glioma even in the presence of neutralizing antibodies and 
an innate antiviral response.  
 
This is a pilot study designed to study PVSRIPO bioactivity in invasive breast cancer 
following intratumoral injection. The endpoints are explorator y and will guide design of a 
phase I/II study of PVSRIPO and combinations of PVSRIPO with immune checkpoint 
blockade  (for example  PD-1/PD -L1) in women  with breast  cancer.  This pilot study  is funded 
by a grant from the Department of Defense (DoD) entitled “Regional oncolytic poliovirus 
immunotherapy for breast cancer” (Principal Investigator, Smita Nair, Ph.D.).  
 
Although we plan to target the TNBC population as the intended population for this  novel 
therapeutic,  for this feasibility  study  we will broaden  the eligibility  criteria  to include  all tumor 
subtypes, as there is no biologic rationale to support differing toxicities from different 
invasive breast cancer subtypes. After safety is confirm ed in this feasibility study, we will 
focus our efforts on the intended TNBC population.  
 
 
Design  and Procedure  
This pilot study is designed to assess PVSRIPO -mediated intratumoral bioactivity, 
inflammation,  and immune  events  in women  with invasive  breast  cancer.  Enrollment  target 
will include  six women  with invasive  breast  cancer.  Women  with stage  II-IV invasive  breast 
cancer  with at least  1 cm of residual  tumor  after chemotherapy  and scheduled  for standard 
of care surgery will be eligible.  
 
Polio vaccine booster will be administered 1 week, or up to 10 days, prior to PVSRIPO 
injection. On day 0, after pr etreatment biopsy is obtained, 1x108 TCID 50 (tissue culture 
infectious  dose)  of PVSRIPO  will be injected  into the tumor  mass.  On day 14 (range  10-20 
days),  women  will undergo  standard -of-care (SOC)  surgical  resection  of PVSRIPO -treated 
tumor.  Women  will have  follow -up at 1-2 days  after PVSRIPO  injection,  1 month  (± 10 days) 
and 6 months (± 1 month) after PVSRIPO for adverse events, disease status, and whole 
blood draw for research purposes.  
 
Women will undergo a pre -treatment core needle biopsy with collection of research cores 
of tumor tissue prior to intratumoral injection of PVSRIPO. Ten to twenty days after 
PVSRIPO injection, tumor tissue will be collected at the time of SOC surgical tumor 
resection. The surgically res ected tissue will be collected and processed as fresh and 
formalin -fixed paraffin -embedded (FFPE)  tissue. The tissue will  be used to  evaluate tumor  

 
 infiltrating  lymphocytes  (TILs),  CD155  expression,  and inflammatory  and immune  signature 
using arrays. Any subjects who do not have evaluable tumor tissue from both the pre - 
treatment biopsy and post -treatment surgery will be replaced.  
 
Additionally,  inflammatory  and immune  analysis  will be conducted  using  blood  obtained  on 
day -7 (range day -7 to -10, before polio vaccine booster), day 0 (before PVSRIPO 
injection), day 2 to 5 (range day 1 -2 after PVSRIPO), day 14 (range day 10 to 20 after 
PVSRIPO, which is before surgery) and in follow -up at months 1 (± 10 days) and 6 (± 1 
month) aft er PVSRIPO. Blood will be analyzed for inflammatory and immune signature 
using  arrays,  immune  cell composition  (antigen  presenting  cells,  B cells and T cells),  T cell 
activation by flow cytometry and B cell activation by ELISA and peptide arrays. This pilo t 
study will enable a phase I/II study of PVSRIPO and combinations of PVSRIPO with 
immune checkpoint blockade (for example PD -1/PD -L1) in women with advanced breast 
cancer.  
 
Selection  of Subjects  
Eligibility Criteria: This pilot study will include women w ith stage II -IV invasive breast 
cancer scheduled to undergo surgical resection. Target enrollment is six women with 
invasive  breast  cancer  over 24 months.  Patients  will be recruited  among  patients  receiving 
their treatment for breast cancer at Duke Cancer Institute (DCI). Any subjects who do not 
have  evaluable  tumor  tissue  from both the pre-treatment  biopsy  and post-treatment  surgery 
will be replaced.  
 
Inclusion  Criteria  
• Age > 18 years  
• Confirmation  of invasive  breast  cancer  including  any of the following:  
o Triple -negative breast cancer defined as receptor status being estrogen receptor 
expression ≤ 10%, progesterone receptor expression ≤ 10%, and HER2/Neu 
expression by IHC 0 or 1+, or 2+ with fluorescence in situ hybridization confirming 
no amplification of HER2 on a pretreatment tumor sample.  
o Hormone positive breast cancer  defined as receptor  status  being estrogen receptor 
expression > 10%, progesterone receptor expression > 10% prior to initiation of 
chemotherapy.  
o HER2+ breast cancer defined as HER2/Neu exp ression by IHC 3+ or fluorescence 
in situ hybridization confirming amplification of HER2 on a pretreatment tumor 
sample prior to initiation of chemotherapy.  HER2+ and hormone positive (ie triple 
positive) breast cancers are included in this study.  
• Stage II -III invasive breast cancer with ≥ 1 cm of residual tumor based on MRI, 
mammogram, ultrasound, or breast clinical exam as SOC after completion of neoadjuvant 
chemotherapy, OR Stage IV BC with ≥ 1 cm locally recurrent disease (i.e. chest wall 
recurrence onl y) 
• ECOG ≤ 1 
• Positive  serum  anti-PV titer prior to biopsy  
• Received a boost immunization with trivalent inactivated IPOL™ (Sanofi -Pasteur) at least 
1 week prior to administration of the study agent  
• Hemoglobin  ≥ 9.0 g/dl, ANC  ≥ 1,000  cells/µl,  platelets  ≥ 100,000  cells/µl  

 
 • Women  must have  had last dose  of chemotherapy at least 2 weeks  prior to treatment with 
PVSRIPO  
• Women  must have at least 2 weeks minimum (ideal 3 -4 weeks) of a wash -out period after 
any steroid administration (IV, PO, or intraocular)  
• Serum  creatinine  ≤ 2.0 mg/dl,  serum  SGOT  and bilirubin  ≤ 2 times  ULN (upper  limit of 
normal)  
• Women  must  provide  written  informed  consent  prior to enrollment  on study,  prior to conduct 
of screening procedures and enrollment on study  
• Women  of childbearing  potential  will have  a negative  serum  pregnancy  test at screening  
• Women  of childbearing  potential  must  be willing  to avoid  pregnancy  utilizing  approved  forms 
of contraception for the course of the study through 120 days after PVSRIPO injection  
• Surgical  resection  of the tumor  is planned  and patient  is willing  to undergo  surgical  resection 
of the cancer  
 
Exclusion  Criteria  
• T1 N0 invasive  breast  cancer  
• Breast  cancer  with skin necrosis  
• Concurrent  immune  therapy,  chemotherapy,  or steroid  therapy  
• Is currently  participating  in or has participated  in a study  of an investigational  agent  or using 
an investigational device within 4 weeks prior to polio vaccine b ooster  
• Has a known  diagnosis  of immunodeficiency  
• Has a known  additional  malignancy  that is progressing  or requires  active  treatment  
• Has known  active  central  nervous  system  metastases  and/or  carcinomatous  meningitis  
• Has an active autoimmune disease requiring systemic treatment within the past 3 months 
or a documented history of clinically severe autoimmune disease or a syndrome that 
requires systemic steroids or immunosuppressive agents  
• Has an active  infection  requiri ng systemic  therapy  
• Has known psychiatric or substance abuse disorders that would interfere with the 
requirements of the trial  
• Is pregnant, breastfeeding, or expecting to conceive children within the projected duration 
of the trial, starting with the scree ning visit through 120 days after trial treatment  
• Has received prior therapy with an anti -PD-1, anti -PDL-1, anti -PDL-2, anti -CD137, or anti - 
CTLA -4 (or any other antibody or drug specifically targeting T cell co -stimulation or 
checkpoint pathways)  
• Has a known  history  of Human  Immunodeficiency  Virus  (HIV)  
• Has known  active  Hepatitis  B or Hepatitis  C 
• Active  liver disease  with elevated  transaminases  > 2x ULN 
• Has received  a live vaccine  within  30 days  prior to PVSRIPO  treatment  
o Inactivated  vaccines  are acceptable  and are not an exclusion  criterion  
Duration  of Study  
This pilot study will accrue 6 women with invasive breast cancer. Follow -up will include 
immunological assessments at 1 -2 days post -PVSRIPO injection, 1 month and 6 months 
post-PVSRIPO for blood draws.  

 
 Data  Analysis  and Statistical  Considera tions  
Six women  with invasive  breast  cancer  will participate  in this clinical  pilot study,  in which  we 
will explore PVSRIPO bioactivity. Any subjects who do not have evaluable tumor tissue 
from both the pre-treatment  biopsy  and post-treatment  surgery  will be replaced.  Descriptive 
statistics will be used to summarize inflammatory and immune signatures in tumor and 
blood,  tumor  infiltrating  immune  cell analysis,  changes  in immune  cell composition  in blood, 
and changes in T cell activation in blood. As such, the correlative studies and the pilot 
clinical  study  design  are part of Aim 1 of the funded  DoD grant  application  entitled  “Regional 
oncolytic poliovirus immunotherapy for breast cancer” (Principal  Investigator, Smita Nair, 
Ph.D.).  
 
 
6 STUDY  SCHEMA  
 
 
 
 
 
 
Figure  1. Study  Schema  PVSRIPO  for Invasive  Breast  Cancer.  

 
 7 BACKGROUND  AND  SIGNIFICANCE  
Study  Disease  
Breast  cancer  is the most  common  cancer  in women,  with an estimated  246,660  new 
diagnoses  in 2016,  and is the second  leading  cause  of cancer  death  in women,  with an 
estimated  40,450  women  in the United  States  dying  from the disease  in 2016  (1). Breast 
cancer  is a heterogeneous  disease  comprising  several  molecular  subtypes,  based  on 
receptor status, specifically the estrogen receptor (ER), progesterone receptor (PR), and 
human  epidermal  growth  factor  2-neu (HER2)  receptor.  These  receptors  are both 
prognostic  but also  predictive of response to  targeted therapy.  Altho ugh often curable when 
localized to the breast and lymph nodes, on the whole, breast cancer remains incurable for 
most women in  the metastatic  setting ( 2). An  estimated  20% to 30% of women  diagnosed 
with invasive breast cancer will have a recurrence and may eventually die of their disease 
(Department of Defense (DoD) Breast Cancer Research Program (BCRP), “The Breast  
Cancer Landscape”).  
 
Triple Negative Breast  Cancer  (TNBC)  refers  to tumors  lacking  the expression  of estrogen 
receptor  (ER),  progesterone  receptor  (PR),  and the human  epidermal  growth  factor  receptor 
2 (HER2)  and portends  a poor prognosis  compared  with tumors  expressing  these  receptors. 
These  tumors  account  for about  15% of all breast  cancers  and have  been  shown  to be more 
aggressive  than other  tumor subtypes.  These  women are  diagnosed  at an earlier  age 
and have a higher risk of local and distant recurrence ( 3). The higher risk of distant 
metastases results in an elevated 5 -year mortality rate compared to ER positive cancers 
(4). In addition, the paucity of targeted treatment available for TNBC likely contributes to 
the lower survival rate. Despite the risk of increased local recurrence and distant 
metastases, standard criteri a are used to select the approach to local therapy as more 
extensive surgeries have not been shown to improve survival ( 3). At the time of distant 
recurrence, there are no standard of care approaches for systemic chemotherapy. 
Common  chemotherapies  utilize d in the neoadjuvant,  adjuvant,  and metastatic 
setting  for invasive  breast  cancers  include anthracyclines,  cyclophosphamide, 
taxanes, capecitabine, eribulin, vinorelbine, and platinums. In addition to these 
chemotherapies, common anti -HER2 treatments used in HER2+ breast cancer include 
trastuzumab, pertuzumab, T -DM1, and lapatinib.  
 
Immunotherapy has been demonstrated to mediate regression of large bulky tumors in  
the stage IV setting in multiple clinical settings, resulting in improved overall and disease 
free survival  in melanoma  and non-small  cell lung cancer,  as well as promising 
objective  response rates in head and neck, gastric, and urothelial cancers ( 5-10). The 
presence  of tumor  infiltrating  lymphocytes  (TILs)  correlates  with a favorable 
prognosis  in various  malignancies  including  TNBC  (11). Several  phase  I/II clinical 
trials targeting the immune checkpoint PD -1/PD -L1 pathways in metastatic TNBC have 
shown promising results with overall response rates of 18 -20% ( 9, 12). 
 
This is a pilot study  designed  to examine  PVSRIPO  bioactivity  in breast  cancer 
following intratumoral  injection.  The endpoints  are exploratory  and will guide  a phase  I/ 
II study  of PVSRIPO and combinations of PVSRIPO with immune checkpoint blockade in 
women with breast cancer. Although we plan to target the TNBC population as the 
intended population  

 
 for this novel therapeutic, for this feasibility study we will broaden the eligibility criteria to 
include all tumor subtypes, as there is no biologic rationale to support differing toxicities 
from different invasive breast cancer subtypes. After safety is confirmed in this feasibility 
study we will focus our efforts on the i ntended TNBC population.  
 
Study  Agent  
PVSRIPO is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a 
heterologous  internal  ribosomal  entry  site (IRES)  derived  from the human  rhinovirus  type 2 
(HRV2).  Poliovirus  receptor  is mediate d by the poliovirus  receptor,  CD155,  an oncofetal  cell 
adhesion molecule, which is widely expressed ectopically in malignancy, e.g. invasive 
breast cancer. Tumor specificity is mediated by selective expression of CD155 in invasive 
breast cancer. Translation is repressed at the heterologous HRV2 IRES in no rmal breast 
tissue and a supportive environment for PVSRIPO translation, growth, and cytotoxicity is 
mediated by universally active protein kinase C (PKC) -Ras-Erk signaling to translation 
machinery in cancers. PVSRIPO is administered intratumorally. Since PVSRIPO is a 
version  of the serotype  1 live-attenuated  (Sabin)  poliovirus  vaccine  (PV1),  its immunogenic 
properties and potential for long -term sequelae are expected to be similar.  Poliovirus 
serotype 1 (SABIN) (PV1S) has been safely administered to >10 bi llion individuals 
worldwide without untoward long -term immunogenic sequelae. The pre -clinical data 
described below was included in the funded DoD grant application to provide rationale for 
this pilot study.  
7.2.1  Pre-Clinical  Experience  
For details about the pre -clinical experience with PVSRIPO, please refer to the 
Investigator’s Brochure for PVSRIPO.  
 
PVSRIPO tumor tropism:  PVSRIPO has natural cancer tropism, due to widespread 
ectopic  expression  of the poliovirus  receptor  (PVR)  CD155  in solid cancers,  where  it 
may serve  as a tumor  immune  evasion  strategy  (13-17). Despite  neuronal 
incompetence,  PVSRIPO  is highly  cytotoxic  in neoplastic  cells ( 17). PVSRIPO’s oncolytic 
efficacy depends on  ectopic  CD155  expression  and unhinged  MAPK -signals to 
translation  machinery.  Both properties  define  most  malignancies,  including  breast 
cancer.  Efficient  tumor  tropism  and rapid,  violent  cytotoxicity  distinguish  PVSRIPO 
from other oncolytic viruses. PVSRIPO uniquely has oncolytic efficacy desp ite pre - 
existing  neutralizing  antibodies  and viral cell killing  proceeds  in the presence  of an 
active innate antiviral response ( 18, 19). 
 
Figure 2A depicts CD155 expression on breast cancer cell lines and primary breast  
tumor tissue ( 20) (de -identified primary tissue was used and the sub -type of primary  
tumor tissue was not determined). Note that CD155 is not expressed on normal breast 
epithelial cult ures (S2N).  PVSRIPO  exhibits  anti-tumor  activity  in breast  cancer  models 
of brain metastases and leptomeningeal disease, which are notoriously refractory to 
therapy ( 20) (Figure 2B ). Figure 3 depicts CD155 expression on primary triple negative 
breast tumor  tissue.  

 
  
 
Figure  2. Breast  Cancer  Susceptibility  to PVSRIPO.  A. CD155  expression  in breast  cancer  cell 
lines and primary  breast  cancer  tissues  by western  blot. B. PVSRIPO  efficacy  in vivo. Rats (n=10)  with 
intrathecal xenografts were treated once  with PVSRIPO at 1x107 pfu (open triangles) or 1x109 pfu 
(closed squares), 3 days after tumor implant. UV -inactivated PVSRIPO was used as control (closed 
diamonds).  
 
 
Figure 3. Immunohistochemistry for the PV R eceptor (CD155) in 19 Triple -Negative 
Breast  Cancer  Cases.  For methods  and detailed  information  on the assay, 
expression  scoring, etc. see Chandramohan et al. (21). The table summarizes expression 
scores  in the 19 cases. The numbered panels show IHC results for the corresponding cases 
in the table. Size bars represent 1 mm (7, 14) or 100 mm (4, 8, 10, 17).  
 
Molecular mechanisms of PVSRIPO tumor specificity: PVSRIPO targets constitutively 
active  Raf-Erk1/2  signal  transduction  to translation  machinery  via Erk1/2  to downstream  

 
 MAPK -interacting  kinases  and to eIF4G  to generate  conditions  that favor  5’ 
methyl -7- guanidine cap -independent, IRES -mediated translation ( 22-24). The Raf -Erk1/2 
pathway is a central gene regulatory node in malignancy that is recalcitrant to small - 
molecule inhibitors, due to drug resistance mechanisms that restore Erk1/2 activit y, for 
example  to trastuzumab  in breast  cancer  (25). PVSRIPO  oncolysis  depends on active 
Raf-Erk1/2 signals thus exploiting  an essential  mitogenic  mechanism  in cancer. 
PVSRIPO  causes  potent  cytotoxicity, with irreversible, lethal effects on infected host 
cells as early as 90 min post PVSRIPO  infection  (26). The TNBC  cell line MDA - 
MB231  and the triple -negative inflammatory breast cancer (IBC) cell line SUM149, are 
susceptible to PVSRIPO -mediated lysis and express CD155 ( Figure 4 ). Lethal  
PVSRIPO -mediated cy totoxicity results in the loss of intact eIF4G and the generation of 
the eIF4G cleavage product ( Figure 4A ) (27). 
 
Figure  4. PVSRIPO  Cytotoxicity  in Breast  Cancer  Cell Lines.  Breast  cancer  cell lines,  MDA - 
MB231 and SUM149, were infected at multiplicity of Infection (MOIs) of 0.1 or 10 with 
PVSRIPO. A. Lysates were collected at the denoted intervals and tested by immunoblot for 
markers of viral cytotoxicity (eIF4G cleavage), host cell demise (PARP cleav age), viral 
replication (viral proteins P2/2BC/2C), and antiviral responses (p -eIF2α(S51)/IFIT1/ISG15). 
Loss of cellular proteins (e.g. tubulin) and viral protein at later time  points correlates with lysis 
of infected cells. B. Cells were infected at an MO I of 0.1 and harvested at 48 h post infection 
(hpi) for analysis  of MHC  class  I and CD155  expression  by flow cytometry  (light  grey,  uninfected 
cells stained with isotype control; dark grey, uninfected cells stained for MHC or CD155; and 
red, infected cells  stained for MHC or CD155).  
 
PVSRIPO activates dendritic cells : PVSRIPO oncolysis releases tumor antigens and 
generates DAMPs and PAMPs (damage -associated and pathogen -associated molecular 
patterns) that stimulates immune cells ( 28). Poliovirus RNA is a cl assic PAMP that 
engages cytoplasmic pattern recognition receptors and downstream responses (Mda5 - 
Stat1 -IFN/) in immune cells.  Poliovirus  naturally targets antigen presenting cells 
(APCs), such as macrophages, monocytes, and dendritic cells (DCs), via CD 155. To 
delineate the effects of PVSRIPO on DCs, we examined markers of cytotoxicity and 
activation status  on antigen presentation.  DCs infected with PVSRIPO at MOI of 1, 10, 
and 100 did not exhibit lytic  

 
 cytoxicity as compared to lytic cytot oxicity in cancer cells infected with PVSRIPO ( Figure 
5A). Viral propagation  was detected,  however,  in sharp  contrast  to cancer  cells,  did 
not yield progeny  beyond  background  levels  (Figure  5A) (29). An increase  in 
Stat1  phosphorylation (which leads to increased Stat1 total protein) followed by the 
upregulation of interferon (IFN) -stimulated genes ISG15, IFIT1, and MDA5 protein, signify 
the activation of  type-I IFN responses  (Figure  5B) (27). Inefficient  cleavage  of eIF4G 
and PARP  and decreased 2C expression following infection, suggests severe limitations 
on viral replication and  cytotoxicity.  This is in sharp  contrast  to what  we observe  in 
tumor  cells treated  with PVSRIPO  (Figure  4). In animal  tumor  models,  there  is 
histologic evidence for virus -mediated tumor cell killing and indirect host -mediated 
inflammatory  responses  focused against tumor ( 24, 30-33). 
 
Figure  5. Infection  and Activation  of Dendritic  Cells  (DCs)  by PVSRIPO.  Human  monocyte - 
derived DCs were infected with PVSRIPO at MOI of 1, 10, and 100. A. LDH-release assay 
(top) and viral  progeny  (bottom)  analysis was  conducted  using  infected DCs  and compared to 
infected DM6/MDA -MB231 cells. B. Western blot analysis was conducted at the designated 
time points post infection (PI). PVSRIPO viral protein (2C) detection signifies productive 
infection. An increase in Stat1 phosphorylation (which leads to increased Stat1 total protein) 
followed  by the upregulation  of IFN-stimulated  genes  ISG15,  IFIT1,  and MDA5  protein,  signify 
activation of IFN responses. Inefficient cleavage of eIF4G and PARP and decreased 2C 
expression  following  infection, suggests  severe limitations  on viral  replication  and cytotoxicity.  
 
To examine if presence of PAMP s and DAMPs in PVSRIPO oncolysate activates DCs, 
tumor lysates were collected after exposing tumor cells to mock - or PVSRIPO -infection 
(MOI  = 0.1; 48h) and treating  human  monocyte -derived  DCs with the resulting 
oncolysate ( Figure 6 ) (27). To control for the effects of infectious PVSRIPO particles 
present  in the oncolysate on DCs (~5x108 pfu/mL), virus was removed using a 100kD 
filter.  This approach  removes all infectious virus but does not remove IFN/dsRNA/HMGB1 
or other conceivable PAMP s/DAMPs. Exposure to oncolysate increased DC co - 
stimulatory molecule expression  

 
 and other  markers  of DC activation  (Figure  6B). This effect  was mitigated  by 
100kD filtration, suggesting that PVSRIPO infection may actively participate in DC 
activation ( 27). 
 
Figure 6. PVSRIPO -Induced Oncolysate Causes DC Activation in a Virus Dependent 
Fashion. A. Outline of in vitro human DC activation experiment. B. PVSRIPO -induced tumor 
lysate (PVSRIPO oncolysate)  activates  human DCs. DCs  were generated ( 34) from HLA -A2+ 
donor cells. Supernatant from untreated or PVSRIPO -infected (MOI = 0.1; 48hpi) tumor cells 
were either unfiltered or filtered through a 100 kD filter. DCs were treated with the resulting 
supernatants  for 24 hours.  Standard  immature  DCs (iDCs ) or DCs matured  in cytokine  cocktail 
(mDCs ) were used as controls. Flow cytometry was used to assess DC activation/maturation 
phenotype  and viability.  This experiment  was repeated  twice  and representative  data is shown.  
7.2.2  Clinical  Experience  
Clinical  efficacy  of OncPV  therapy  against  recurrent  WHO  Grade  4 malignant  glioma 
PVSRIPO has been tested in a phase I study in subjects with recurrent WHO Grade 4 
malignant glioma and has generated a durable clinical response in approximately 20% of 
patients. These responses occurred despite prior disease progression following surgical  
resection,  cranial  radiation  therapy,  chemotherapy  (temozolomide,  TMZ),  and (sometimes) 
bevacizumab. Fifteen patients were enrolled into the PVSRIPO dose -escalation portion of 
this phase I study. Dose was rapidly escalated from 1x108 TCID 50 (dose level 1)  to 1x1010 
TCID 50 (dose level 5) after which dose was reduced due to long -term steroid or 
bevacizumab therapy to control inflammatory reaction secondary to PVSRIPO -mediated 
immune  response.  For more  information  about  the clinical  findings  of PVSRIPO,  refer to the 
Investigator’s  Brochure  for PVSRIPO.  Based  on the original  dose  finding  and safety  study 
in patients with recurrent malignant glioma (Study Registry ID: [REMOVED]; 
Duke IRB Pro00031169), we will use 1x108 TCID 50 (dose level 1) in women with invasive 
breast cancer.  
We have  chosen  to use 1x108 TCID 50 (dose  level 1 from the phase  1 dose -escalation  study 
in patients with recurrent WHO Grade 4 malignant glioma) for the following reasons.  
1. In the dose escalation study conducted in patients with malignant glioma, patient 1 
received dose level 1, 1x108 TCID 50. This patient responded favorably to PVSRIPO 
therapy  and was disease -free 60+ months  after receiving  a single  intratumoral  injection  

 
 of PVSRIPO.  
2. Brain  inflammation  in the area of the tumor  or immediately  adjacent  was the main  toxicity 
associated with intratumoral infusion of PVSRIPO and the primary reason for dose 
reduction in the phase I brain tumor study and use of dose level -1 (5 x 107 TCID 50) in 
the Phase 2 glioma trial. There were no signs of encephalitis, systemic toxici ty or 
systemic inflammatory processes. Given that the breast is not in a physiologically 
confined space (like brain in the cranium) the effects of inflammation due to PVSRIPO 
are not of significant clinical impact. Additionally, the breast tumor will be re sected 10 - 
20 days  following  PVSRIPO  infusion  therefore  limiting  the time in which  the patient  may 
experience discomfort from tumor site hyper -inflammation.  
3. A higher  dose  is warranted  in this setting  given  that there  may be some  systemic  leakage 
upon injection, therefore requiring an overall higher dose to ensure that a substantial 
amount of the PVSRIPO remains in the tumor. We will therefore start with dose level 1 
(1x108 TCID 50) from the phase 1 recurrent WHO Grade 4 malignant glioma stu dy, to 
ensure  that we elicit a response  in tumor  (both  tumor  killing  and immune  consequences) 
post-PVSRIPO in this pilot study.  
 
Study  Purpose  and Rationale  
PVSRIPO, a recombinant oncolytic poliovirus, has shown promising results in recurrent 
malignant  glioma  when  administered  intracerebrally.  Once  administered,  PVSRIPO  enters 
tumor cells through the poliovirus receptor CD155, which is overexpressed in solid 
malignancies.  As such,  it both specifically  targets  and destroys  tumor  cells that it enters  and 
initiates innate and adaptive immune events in the host.  
 
A phase I clinical trial of PVSRIPO in recurrent malignant glioma patients has yielded 
durable  complete  radiographic  and clinical  responses  with a proportion  of patients  achieving 
prolonged disease survival up to 61+ months. The first subject treated with PVSRIPO is 
alive and well 5 years  after PVSRIPO  administration.  PVSRIPO  was granted  Breakthrough 
Therapy Designation by FDA/CBER on May 16th, 2016.  
 
As CD155 is also overexpressed in all subtypes of invasive breast cancer, a pilot study to 
examine  the effects of intratumoral  injection  of PVSRIPO  into invasive  breast  cancer  tumors 
in 6 women is of interest. Importantly, if effective, this will lead to a phase I/II trial of 
PVSRIPO and combinations of PVSRIPO with immune checkpoint blockade (for example 
PD-1/PD -L1) in women with triple negative breast cancer. Of note, PD -1/PD -L1 blockade 
has already demonstrated some clinical efficacy in women with TNBC.  
 
Rationale:  The rationale  for doing  this pilot clinical  study  in six women  with invasive  breast 
cancer is as follows:  
1. To characterize  intratumoral  PVSRIPO  injection  in a non-CNS  cancer  
2. To investigate  inflammation  and immunity  in tumor  tissue  post-PVSRIPO  treatment. 
PVSRIPO treatment is showing promise in malignant glioma patients but the tumor 
tissue is not accessible to examine PVSRIPO bioactivity. This pilot study in wom en 
with accessible invasive breast cancer would enable investigation of PVSRIPO 
bioactivity in tumor tissue.  
3. To demonstrate that post -transcriptional gene regulatory principles that mediate 
PVSRIPO tumor cytotoxicity apply to breast cancer.  

 
 8 OBJECTIVES  AND  ENDPOINTS  
To examine oncolytic poliovirus (OncPV) bioactivity in tumor tissue after intratumoral 
administration of PVSRIPO in women with invasive breast cancer.  
 
Objectives  (Exploratory) : 
To investigate PVSRIPO -mediated inflammation and immunity in women with stage II-IV 
invasive breast cancer.  
1. Primary Exploratory Objective : To describe the change in the amount of tumor 
infiltrating  immune  cells in tumor  tissue  pre- and post-injection  of PVSRIPO  by H&E 
(Haemotoxylin and Eosin).  
2. Other  Exploratory  Objectives : 
a. To examine  tumor  tissue  pre- and post-injection  of PVSRIPO  for inflammatory 
and immune signature using arrays, CD155 expression by 
immunohistochemistry (IHC), immune cell infiltrate by IHC and tumor 
infiltrating immune cells using flow cytometry (post -injection only).  
b. To examine blood for inflammatory and immune signa ture using arrays, 
immune  cell composition  (antigen  presenting  cells,  B cells and T cells),  T cell 
activation  by flow cytometry  and B cell activation  by ELISA  and peptide  arrays. 
Blood will be collected on day -7 (range day -7 to -10, before polio vaccine 
booster), day 0 (before PVSRIPO injection), day 2 (range day 1 -2 after 
PVSRIPO), day 14 (range day 10 to 20, after PVSRIPO before surgery) and 
in follow -up at months 1 (± 10 days, after PVSRIPO) and 6 (± 1 month, after 
PVSRIPO).  
 
Hypothesis  
Administration of oncolytic poliovirus, PVSRIPO, in the tumor causes inflammation, which 
stimulates innate and adaptive immune activation, in invasive breast cancer.  
 
9 INVESTIGATIONAL  PLAN  
Study  Design  
This is a single institution pilot study designed to assess PVSRIPO -mediated intratumoral 
bioactivity, inflammation and immune cell infiltration in 6 patients with invasive breast 
cancer. To maximize immunological stimulation, we will wait at least 2 weeks  (ideal 3 -4 
weeks) after the last dose of chemotherapy or steroids to administer the polio vaccine 
booster.  PVSRIPO  will be injected  into the tumor  mass  at 1x108 TCID 50 7-10 days  after polio 
vaccine booster is administered.  
 
Biopsy  material  will be obtaine d from tumor  tissue  immediately  prior to virus  administration 
and resected tumor  tissue will  be obtained  at 10-20 days (ideally  12-16) after PVSRIPO at 
the time of surgical resection. The PVSRIPO -treated tumor tissue will be transported to 
Surgical Pathology by the Brain Tumor BioRepository (BTBR) Team, as directed by Dr. 
Roger McLendon, MD or per clinical protocol, for gross examination and re search tissue 
procurement, thereby safe -guarding the diagnostic integrity of the specimen. Additional 
expertise  in breast  pathology  will be provided  by Dr. Edgardo  Parilla  Castella,  MD, PhD.  

 
 Tissue deemed appropriate for collection (i.e. wast eful excess and of no diagnostic value) 
will be collected  by the Brain  Tumor  BioRepository  (BTBR)  Team,  as directed  by Dr. Smita 
Nair, PhD, and transported to her lab for correlative molecular and immune analyses. Our 
primary  objective  is to determine  chan ge in the amount  of tumor  infiltrating  immune  cells in 
tumor tissue pre - and post -injection of PVSRIPO by H&E. We will also evaluate 
inflammatory and immune signatures using inflammatory and innate/adaptive arrays, 
CD155 expression and immune cell infiltrate by IHC  and tumor infiltrating immune cells by 
flow cytometry (post -injection only).  
 
Additionally,  inflammatory  and immune  analysis  will be conducted  using  blood  obtained  on 
day -7 (range day -7 to -10, before polio vaccine booster), day 0 (before PVSRIPO 
injection), day 1 -2 (after PVSRIPO), day 14 (range day 10 to 20 after PVSRIPO, which is 
before  surgery),  and in follow -up at months  1 (± 10 days)  and 6 (± 1 month)  after PVSRIPO. 
Blood will be analyzed for inflammatory and immune signature using arrays, immune cell 
composition  (antigen  presenting  cells,  B cells and T cells),  T cell activation  by flow cytometry 
and B cell activation by ELISA and peptide arrays. Immune cell composition and T cell 
activation in blood will be done using DuraClone IM panels from Beckman Coulter.  
 
Safety  Considerations  
9.2.1  Surgical  Complications  
Patients  undergoing biopsy  and excision  of breast tumors  may develop infection  at site 
of injection or breast tissue removal, cellulitis, or abscess formation. Seromas or 
hematomas  may also be a complication  in this setting.  The risk of perioperative  infection 
will be the same  as encount ered routinely  for breast  surgery.  Patients  will be monitored 
throughout  the course  of the study  for any signs  and symptoms  of infection.  If an active 
infection is suspected, patients will be cultured and treated with appropriate antibiotics 
and/or undergo incision and drainage procedure.  
9.2.2  Anesthesia  
Patients  undergoing  general  anesthesia  may be subjected  to associated  risks including 
pneumothorax,  pneumonia, airway injury, hypotension, myocardial infarction, stroke, 
hepatic and renal injury and death.  
9.2.3  Poliomyelitis  
PVSRIPO has been tested in non -human primates (NHPs) according to the WHO 
standardized monkey neurovirulence tests. These tests reveale d the absence of 
neuropathogenic properties, evident as failure to induce symptoms of poliomyelitis in 
NHPs after intracerebral inoculation of virus. In addition, the use of intracerebral 
PVSRIPO in human subjects with recurrent malignant glioma in phase I  trials have not 
induced  symptoms  of poliomyelitis.  However,  PVSRIPO  are replication -competent  viral 
agents that, in principle, retain the potential to cause motor neuron damage. Possible 
complications include transient or permanent  mono - or paraparesis, p aralysis, and life - 
threatening respiratory insufficiency.  
9.2.4  Virus  Recombination  and Mutation  
PVSRIPO  retains  the ability  to alter its genome  during  replication  upon  administration  to 

 
 patients. Various mechanisms are known to lead to genetic adaptation, including 
spontaneous mutagenesis and recombination that may give rise to viral progeny with 
changed properties. Empirical studies in tissue culture and laboratory animals 
demonstrated t hat prolonged passaging in malignant glioma cells does not select for 
genetic changes in viral progeny. However, the occurrence of such events cannot be 
categorically excluded in patients receiving PVSRIPO. So far, the use of intracerebral 
PVSRIPO in human  subjects with malignant glioma in phase I trials have not 
demonstrated these phenomena.  
9.2.5  Long -Term  Sequelae  of Virus  Injection  
PVSRIPO does not encode foreign genetic material, polioviruses are unable to insert 
viral genetic material in the host genome and  polioviruses are incapable of inducing 
latent or chronic CNS infection. Therefore, PVSRIPO is unable to induce long -term 
expression of foreign polypeptides or long -term persistence of virus replication. Thus, 
there are no long -term neurologic consequences  to intracerebral PVSRIPO 
administration  in study  subjects.  For these  reasons,  no specific  measures  to analyze  the 
potential for persistence of virus replication in the CNS of long -term survivors are 
indicated.  
 
Prolonged  gastrointestinal  propagation  of polioviruses,  associated  with prolonged  virus 
shedding with stool, has been reported in select individuals with acquired or rare 
inherited immunodeficiency disorders. Primate toxicology results indicate that 
extraneural dissemination and shedding of PVSRIPO with stool do not occur after 
intracer ebral inoculation. In addition, the use of PVSRIPO in human subjects with 
recurrent malignant glioma in phase I have not demonstrated this phenomena.  
9.2.6  Risks  of Phlebotomy  
Drawing blood or inserting an intravenous catheter into an arm vein may result in 
bruising or swelling in the area of the insertion, bleeding at the site of the needle 
puncture, light headedness, fainting and very rarely, local infection, which may be 
severe. These risks are reduced by the fact that the blood will be drawn by a qualified 
physician, nurse or phlebotomist (a professional trained to draw blood).  
9.2.7  Risks  to Household  Contacts  of Study  Subjects  
Primate  toxicology  studies  showed  that intracerebral  infusion  of PVSRIPO  does  not lead 
to extraneural dissemination or replication and, hen ce, is not associated with virus 
shedding. In addition, this also has not been observed with the use of PVSRIPO in 
human subjects with recurrent malignant glioma in phase I trials. Therefore, and 
because poliovirus transmission occurs via the fecal -oral ro ute, the likelihood of 
unintended exposure of patient household contacts is exceedingly low. If accidental 
exposure  occurred,  it would  equal  the risk of exposure  to any type 1 Sabin  vaccine  virus 
or vaccine  virus  derivatives.  Thus,  in essence,  exposure  with PVSRIPO  is equal  to oral 
immunization with a safe version of type 1 Sabin. Since type 1 Sabin vaccine virus or 
vaccine virus derivatives have to be considered part of the human environment, 
exposure to PVSRIPO would not represent an added ris k beyond the possibility for 
exposure that already exists. Study subjects will be advised of the risks of exposure to 
unvaccinated household contacts.  
 
 
9.2.8  Unacceptable  Toxicities  
Clinical  trials  using  PVSRIPO  in breast  tumor  patients  have  not been  performed.  Since 
the overall risk classification of this research is unknown we plan to take the following 
approaches to ensure patient safety:  
I. We will stagger enrollment of each patient by at least 4 weeks, which will be 
sufficient time to implement dose reduction or other safety measures based on 
adverse events observed.  
II. The study will only treat 6 patients total. However, the trial will be paused for 
enrollment and undergo reevaluation if two patients have any Grade 3 or any 
Grade 4 toxicity that is  not reversible within 2 weeks after surgery (~24 -34 days 
after PVSRIPO, depending on when the surgery is performed), or any life - 
threatening  event,  or treatment -related  death  will be considered  an unacceptable 
toxicity. Any grade 2 or higher serious auto immune toxicities particularly those 
affecting vital organs (e.g. cardiac, renal, CNS) will be considered an 
unacceptable toxicity. Also, the study will be paused to enrollment if a patient 
death  occurs  within  a month  after PVSRIPO  injection  possibly  or likely  related  to 
PVSRIPO.  
 
Rationale for Selection of Dose, Regimen, and Treatment Duration 
The dose of PVSRIPO for this trial was selected based on IND -directed toxicity studies 
and on experience  from a  phase  I study  in adults  with recurrent  WHO  grade  IV malignant 
glioma. For more information on the results from the dose -finding study, please refer to 
the Investigator’s Brochure for PVSRIPO.  
 
We have chosen to use 1x108 TCID 50 (dose level 1 from phase 1 dose -finding malignant 
glioma trial) f or the following reasons.  
1. In the dose escalation study conducted in patients with recurrent malignant glioma, 
patient 1 received dose level 1, 1x108 TCID 50. This patient responded favorably to 
PVSRIPO therapy and was disease -free 60+ months after receiving a single 
intratumoral injection of PVSRIPO.  
2. Brain  inflammation  in the area of the tumor  or immediately  adjacent  was the main  toxicity 
associated with intratumoral infusion of PVSRIPO and the p rimary reason for dose 
reduction  in the phase  I brain  tumor  study.  Because  of this, dose  level -1 (5 x 107 TCID 50) 
is being  investigated  in the phase  2 recurrent  malignant  glioma  study  in adults  and phase 
1b study  in pediatric  patients.  There were no signs  of encephalitis, systemic  toxicity  or 
systemic inflammatory processes. Given that the breast is not in a physiologically 
confined space (like brain in the cranium) the effects of inflammation due to PVSRIPO 
are not of significant clinic al impact. Additionally, the breast tumor will be resected 10 - 
20 days  following  PVSRIPO  infusion  therefore  limiting  the time in which  the patient  may 
experience discomfort from tumor site hyper -inflammation.  
3. A higher dose is warranted in the breast cancer setting given that there may be some 
systemic leakage upon injection, therefore requiring an overall higher dose to ensure 
that a substantial amount  of the PVSRIPO  remains  in the tumor.  We will therefore  start 
with dose level 1 (1x108 TCID 50) from the phase 1 malignant glioma study, to ensure 
that we elicit a response in tumor (both tumor killing and immune consequences) post - 
PVSRIPO in this pilot study.  
 
 4. If a study  pause  occurs  due to adverse  events observed  according  to Section 9.2.8  and 
these  adverse  events  are concluded  to be possibly  or likely  related  to PVSRIPO  injection 
and it is deemed safe  to continue the study, then we will continue to  enroll patients at a 
lower dose of 5x107 TCID 50, the dose currently being investigated in the phase 2 
recurrent malignant glioma study in adults and a phase 1b study in recurrent malignant 
glioma in pediatric patients.  
 
Rationale  for Correlative  Studies  
As this is a pilot stu dy with exploratory endpoints only, correlative studies will be used to 
assess PVSRIPO tumor bioactivity. Specifically, the study will investigate PVSRIPO - 
mediated  inflammation  and immunity  in women  with stage  II-IV invasive  breast  
cancer.  Greater detail is provided in Section 8 . 
 
Early  Study  Termination  
This study  can be terminated  at any time for any reason  by the PI or Sponsor.  If this occurs, 
all subjects on study will be notified as soon as possible. Additional procedures and/or 
follow  up should  occur  in accordance  with Section  12.6, which  describes  criteria 
for Early  Withdrawal of Subject(s).  
 
10 STUDY  DRUG  
Names,  Classification,  and Mechanism  of Action  
PVSRIPO  is the live attenuated  poliovirus  (PV) serotype  1 (SABIN)  vaccine  with its internal 
ribosomal entry site (IRES) element replaced with that of human rhinovirus type 2. IRES 
exchange causes an inability of PVSR IPO to drive translation of its genome in normal  
cells ( 35, 36). Thus, PVSRIPO is devoid of neuropathogenicity after high -dose 
intracerebral  inoculation in non -human primates ( 13) and in humans. Because PVSRIPO 
is a version of the serotype 1 live -attenuate d (Sabin) poliovirus vaccine (PV1), its 
immunogenic  properties  and potential  for long-term sequelae  are expected  to be 
similar. PV1S has been safely administered to >10 billion individuals worldwide without 
untoward long -term immunogenic sequelae. The main  immunogenic effect of 
administration  of PV1S  to human  subjects  is neutralizing immunity to poliovirus.  
 
Supply,  Receipt,  and Storage  
PVSRIPO is  formulated in 50  mM sodium phosphate in  0.9%  sodium chloride, pH 7.4 with 
0.2%  human  serum  albumin.  It is provided  in sterile,  single  use containers.  PVSRIPO  must 
be stored at less than or equal to -70°C. Once thawed, it is a clear colorless liquid with no 
evidence of particulates or foreign matter. The PVSRIPO being utilized in this study was 
manufactured at the Biopharmaceutical Development Program/National Cancer Institute 
(NCI) -Frederick.  
 
Dispensing  and Preparation  
The study  agent  and vehicle  will be supplied  to the Investigational  Pharmacy  by the Sponsor 
or their representative. The study agent will be shipped via approved methods in the 
appropriate  packaging  on dry ice. Storage  of the study  agent  at -70C has been  empirically 
determined  to not compromise  biological  and biophysical  properties  for at least  5 years.  

 
 The agent will be stored long -term in an ultra -low temperature freezer (e.g., less than or 
equal to -80°C freezer).  
 
For aliquot preparation, the agent will be thawed slowly on ice (~4 C) and k ept at that 
temperature. Thawed vials of PVSRIPO are stable at 4°C for 48 hours. The supplier will 
provide the study agent’s potency (as tissue culture infectious doses [TCID]) and will also 
supply the appropriate vehicle for aliquot preparation. Aliquot p reparation will occur in the 
Investigational Pharmacy. All handling of the study agent will occur in a biosafety cabinet 
or a similarly contained environment.  
 
The study agent will be in a disposable, hypodermic needle with a safety sheath to cover 
the nee dle using a one -handed technique after the agent is drawn into the syringe. The 
sheathed  needle  is then removed  from the syringe  containing  the study  agent,  aliquoted  at 
the desired  dose,  and the syringe  will be capped.  The capped  syringe  will be transported  to 
the site of patient  injection  in a ‘ziplock’  bag placed  in a portable  cooler  while  maintaining  a 
temperature of 4°C.  
 
Each patient will be injected with a total intratumoral dose of 1x108 TCID 50 PVSRIPO in 
physiologic  saline  stabilized  with 0.2%  human  serum  albumin.  The injection  surface  will be 
cleaned with Chloraprep or betadine and allowed to dry. A local anesthetic ag ent will be 
applied to the injection area. There will be a single entry point into the breast. The study 
agent in  0.6 mL will be  loaded into  a 1 cc syringe connected to the injection  needle. Under 
direct ultrasound visualization, a 20 or 21 -gauge needle wi ll be inserted into the tumor. 
Following visualization of the needle tip within the tumor, study agent will be injected over 
10-15 seconds by hand injection. The needle tip will then be repositioned to another site 
within  the tumor  and the injection  repeat ed. A total of 3-6 sites will be injected  with the total 
study dose evenly divided among sites. The location of sites will be selected by the 
performing  radiologist  with the aim of evenly  distributing  the study  agent  over the volume  of 
a typically irregularly shaped tumor. All injections will be performed under direct real -time 
ultrasound visualization. The needle will then be removed very slowly.  
 
Post-Injection pressure will be applied to the injection site(s) with sterile gauze for  at least 
30 seconds. The injection site and surrounding area will be swabbed with alcohol. After a 
change of gloves, the injected lesion(s) will be covered with an absorbent pad and dry 
occlusive dressing. Exterior of the occlusive dressing will be wiped with alcohol. Following 
injection and bandaging, the patients will be transferred to clinic 2.2. Vital signs will be 
monitored every 10 minutes for an hour prior  to patient discharge. Patients will be advised 
to keep the injection site(s) covered. Bandage will be replaced when the patient returns to 
the clinic 1 -2 days after PVSRIPO injection. Patients will be advised to leave the dressing 
on for 2-3 more  days.  If the bandage  falls off at home,  the patients  will be asked  to replace 
the bandage.  They  will receive  instructions  on how to replace  bandage  and will be provided 
with gloves  and plastic  Ziploc  disposal  bags.  The old bandage  and gloves  will be placed  in 
the plastic  Ziploc  bag, the bag closed  and then put in regular  plastic  trash  bag for disposal.  
 
Compliance  and Accountability  
Compliance  and accountability  will be monitored  by the Investigational  Chemotherapy  

 
 Service  (ICS)  according  to their standards  of practice  (SOPs).  
 
Disposal  and Destruction  
All materials coming in contact with the study agent, the syringe delivered from the 
Investigational Pharmacy, tubing, dressings or coverings used to protect the trepanation 
site, will be disposed of as biological waste in  the treatment room. Disposal of a ny unused 
or partially used study agent will be the responsibility of the Investigational Pharmacy. All 
surgical materials used in the procedure  and potentially coming into  contact with the study 
agent will be disposable. Used sharps with be disposed in a biohazard sharps container 
and incinerated in final disposal. All personnel caring for the patient will be wearing 
appropriate  safety  devices,  e.g. disposable  gloves,  gown,  and face protection,  which  will be 
disposed  of as biological  waste  in the treatment  room.  Appropriate  hand  hygiene  is required 
before and after any handling of the study agent.  
 
Spill procedure . PVSRIPO can be easily and completely inactivated with household 
bleach. In the event of a spill, the liquid will be absorbed with gauze  then treated as 
biohazardous waste as above. The spill area will then be liberally wiped down with a 20% 
household bleach solution for chemical disinfection. The disinfectant will be left in contact 
with the contaminated  area for at least  30 minutes,  then wiped  away  with wet towels,  which 
will be disposed as biohazard waste as well.  
 
Exposure follow -up. Any virus exposures will be reported to the Employee Health 
Exposure Hotline (115), followed by submission of the Report of Occupational Injury or 
Illness form. There is no specific preventative treatment. Based on the circumstances of 
exposure, employee health may choose to monitor for infection by submitting stool for 
enterovirus culture at 7, 14, and 21 days after an exposure event.  
 
11 SUBJECT  ELIGIBILITY  
Inclusion  and Exclusion  Criteria  
Please  refer to Section 5.4. 
 
12 SCREENING  AND  ON-STUDY  TESTS  AND  PROCEDURES  
Informed  consent  will occur  after confirming  tumor  size by imaging  per SOC between  days 
-28 and -7 After obtaining informed consent and during screening (days -28 to -7), women 
with invasive breast cancer will undergo complete history and physical exam, blood work 
including CBC, CMP, and pregnancy test (if applicable). An ultrasound, mammogra m, or 
breast MRI showing a residual breast tumor at least 1 cm in size before PVSRIPO 
injection is required.  
 
After completing informed consent for the protocol, the patient will receive a polio vaccine 
booster  (day -7). On day 0, an ultrasound  guided  core biopsy  will be performed  at radiology 
prior to injection of PVSRIPO into the tumor. Injection will be performed in Duke Breast 
Radiology  and the patients  will be transferred  to Duke  Cancer  Center  clinic  2-2. Vital signs 
will be monitored  every  15 minutes  for an hour prior to patient  discharge.  On day 10-20 

 
 (ideal 12 -16 days), the patient will undergo SOC surgery. Part of the excised tumor will be 
transported to Surgical Pathology by the Brain Tumor BioRepository (BTBR) Team, as 
directed by Dr. Roger McLendon, MD or per clinical protocol, for gross examination and 
research tissue procurement.  Additional expertise in breast pathology will be provided by 
Dr. Edgardo Parrilla Castellar, MD, PhD.  
 
Tissue deemed appropriate for collection (i.e. wasteful excess and of no diagnostic value) 
will be collected  by the Brain  Tumor  BioRepository  (BTBR)  Team,  as directed  by Dr. Smita 
Nair, PhD, and transported to her lab for correlative molecular and immune a nalyses. 
Surgically resected tissue will be used fresh and/or processed into formalin -fixed paraffin - 
embedded (FFPE) blocks, required for immunohistochemistry and immunofluorescence. 
Additionally,  inflammatory  and immune  analysis  will be conducted  using  blood obtained  on 
day -7 (range day -7 to -10, before polio vaccine booster), day 0 (before PVSRIPO 
injection), day 1 -2 (range day 1 -2 after PVSRIPO), day 14 (range day 10 to 20 after 
PVSRIPO, which is before surgery) and in follow -up at months 1 (± 10 days ) and 6 (± 1 
month) after PVSRIPO. Blood will be analyzed for inflammatory and immune signature 
using  arrays,  immune  cell composition  (antigen  presenting  cells,  B cells and T cells),  T cell 
activation  by flow cytometry  and B cell activation  by ELISA  and peptide  arrays.  Whole  blood 
will be collected for immunological correlates on day -7 (range -7 to -10 just before polio 
vaccine booster), day 0 (before PVSRIPO injection), day 1 -2 and day 14 (range day 10 to 
20 after PVSRIPO,  just before  surgery)  and in follow-up at months  1 and 6 after PVSRIPO.  
 
Table  1. Screening  and On-Study  Tests  and Procedures.  
 
 
Anticipated  Time Frame  Screening 
Day -28 to 
-7  
Day -7  
Day 0 Day 
1-2 Day 10- 
20 Follow - 
up 
Scheduling  Window  
(Days)  -28 to -7 -7 to - 
10 0 1-2 10 to 
20 1, 6 
months  
Informed  consent  X      
Medical  history  X      
Physical  Exam,  vitals  X X X   X 
Wound/injection  site 
evaluation     X X  
Concomitant  medications  Continuous  
12-Lead  ECG  X      
Pregnancy test (whole 
blood - only if 
premenopausal  prior to 
chemotherapy)   
X      
CBC  w/diff  X X X X X  
CMP  X  X  X  
Urinalysis  X      
 
  
 
Anticipated  Time Frame  Screening 
Day -28 to 
-7  
Day -7  
Day 0 Day 
1-2 Day 10- 
20 Follow - 
up 
SOC  MRI, MMG, or 
ultrasound  of tumor  X  X  X1 X2 
Polio  vaccine  booster   X     
PVSRIPO  injection    X    
Tumor  biopsy    X    
Tumor  resection      X  
Whole  blood  for immune  
analysis  (35 mL) X X X X X X 
Blood  for polio  titer (5 mL) X X X  X X3 
SAEs /  AEs  Continuous  
Stool sample*       X4 
Days  
7,14,21,56  
 
Screening  and On-Study  Tests  and Procedures  
• History : Complete history, ECOG status, and physical exam including vital signs, and 
weight, must be obtained within 7 -28 days prior to completion of informed consent.  
• Blood  work : CBC  with differential,  CMP,  and pregnancy  test. Pre-study  laboratory  tests 
must be obtained within 7 -28 days prior to completion of informed consent.  
• Imaging : All participants must have a MRI, MMG or ultrasound after completion of 
chemotherapy (days -28 to -7) showing a breast tumor at least 1 cm in size.  
• Pathology:  Patholo gical report  confirming  diagnosis  of invasive  breast  cancer  prior 
to start of chemotherapy will be required.  
• Systemic imaging : CT chest/abdomen/pelvis, PET scans, ultrasounds, and bone  
scans during the trial are at the discretion of the PI and will be orde red as indicated to 
assess for extent of disease or disease relapse per SOC.  
• *Stool samples : Stool samples will be collected on days 7, 14, 21, and 56 after 
PVSRIPO injection to comply with Duke Biosafety Protocol. This is not a clinic visit. 
Patients will  be given a kit to collect stool that includes the following items: a toilet hat 
specimen collector, tongue depressor(s), a urine sample container, 2 plastic bags, and a 
brown paper bag. Samples will be stored frozen until the next clinic visit.  
Pre-treat ment  Period  
Women  with stage  II-IV invasive breast  cancer  with a residual  tumor  mass  of at least  1 cm 
by imaging,  after completion  of neoadjuvant  chemotherapy  will be included  in this study.  A 
polio vaccine booster will be given 7 to 10 days before PVSRIPO injection. Thirty -five ml 
whole blood will be drawn for immunological profiling before polio vaccine booster.  
 
 
1 At the discretion  of the physician,  MMG  or ultrasound  may be done  the day prior to surgery  
2 MMG  or ultrasound  only done  at the 6 (± 1) month  follow -up visit. 
3 At 1 month  follow -up visit only. 
4 This is a take-home  kit and does  not involve  a clinic/hospital  visit. Days  refer to days  after PVSRIPO.  

 
 Treatment  Period  
Patients  will undergo  a core biopsy  of the tumor  after which  PVSRIPO  will be administered 
via intratumoral  injection  using  ultrasound  guidance  in Radiology.  Core  biopsy  will be tested 
for CD155 expression, immune infiltrate by H&E and IHC, and inflammatory and immune 
signature by arrays. After injection, the patient will be transferred to clinic 2.2. Vital signs 
will be monitored every 10 minutes for an hour prior to patient disc harge. Thirty -five ml of 
whole  blood  will be drawn  for immunological  profiling  prior to PVSRIPO  injection.  Thirty -five 
ml of whole blood will be drawn for immunological profiling 1 -2 days after PVSRIPO 
injection.  
 
End of Treatment  
End of treatment, define d as definitive standard -of-care surgery, will be performed on 
patients  10-20 days  after the PVSRIPO  injection.  Tumor  samples  obtained  from the surgical 
resection will be tested for CD155 expression, immune infiltrate by H&E and IHC, tumor 
infiltrating immune cell profile using flow cytometry, and inflammatory and immune 
signatures using arrays. The excised tumor will be transported to Surgical Pa thology  by 
the Brain Tumor BioRepository (BTBR) Team, as directed by Dr. Roger McLendon, MD or 
per clinical  protocol.  Dr. Edgardo  Parilla  Castellar  will provide  additional  expertise  in breast 
pathology. Tissue deemed appropriate for collection  will be tran sported to Dr. Smita Nair, 
PhD, by the BTBR Team for correlative molecular and immune analyses. Surgically 
resected tissue will be used fresh and/or processed into FFPE blocks, required for 
immunohistochemistry  and immunofluorescence.  Thirty -five ml of whole blood  will be drawn 
for immunological profiling.  
 
Follow -up Period  
Follow  up will be at 1-2 days,  1 month,  and 6 months  after PVSRIPO.  Thirty -five ml of whole 
blood will be drawn at each time point for immunological profiling.  At 6 month SOC visit, 
the patient will undergo an MMG or ultrasound to monitor disease progression.  
 
End of Study  
End of study is defined as after the 6 month follow -up visit. Patient will be removed from 
the trial if they choose to withdraw from the trial or if unable to comply with the study 
requirements, please refer to Section 12.6.1 for more details on early with drawal. The 
decision  to remove  a patient  from trial due to failure  to comply  with study  requirements 
is at the discretion of the PI. Patients will continue to be monitored indefinitely for 
progression, further treatment regimens,  and survival.  
 
Early  Withdrawal  of Subject(s)  
12.6.1  Criteria  for Early  Withdrawal  
Patients  may voluntarily  withdraw  from the study  at any time.  The PI may also withdraw 
a patient from the study at any time based on his/her discretion. Reasons for PI - 
initiated withdrawal may include , but is not limited to the following:  
- Adverse  events  
- Abnormal  laboratory  values  
- Abnormal  test procedure  results  
- Protocol  deviation  

 
 - Administrative  issues  
- Pregnancy  
 
13 SAFETY  MONITORING  AND  REPORTING  
Adverse  Events  
An ‘Adverse  Event’  will be defined  as any adverse  change  from the subject’s  pre-treatment 
baseline condition, including any clinical or laboratory test abnormality that occurs during 
the course of research after the polio vaccine booster is given on day -7. Adverse events 
will be ca tegorized and graded in accordance with the NCI CTC (Version 4).  
 
A ‘Serious Adverse Event’ will be defined as an undesirable sign, symptom or medical 
condition  which  is fatal or life threatening,  requires  inpatient  hospitalization  or a prolongation 
of existing  hospitalization,  results  in persistent  or significant  disability/incapacity,  constitutes 
a congenital anomaly or a birth defect and/or medically significant impairment such that it 
may jeopardize  the subject,  and may require  medical  or surgical  intervention  to prevent  one 
of the outcomes listed above.  
 
A summary of all adverse even ts (not just those considered related to the study drug) will 
be maintained in a 21 CFR Part 11 compliant database. The event will be categorized by 
organ system, relationship to treatment, its grade of severity, and resolution. The PI and 
study statistici an will periodically review the collective adverse events with the intention of 
identifying  any trends  or patterns  in toxicity.  If any such  trends  are identified,  depending  on 
their severity and frequency, a protocol amendment will be considered.  
 
Reporti ng of Serious  Adverse  Events  
SAEs must be reported by the PI to the Sponsor or their designee within 24 hours of 
discovery  if the event  occurs  during  the clinical  study  or within  28 days  of receiving  the study 
drug,  whether  or not the SAE is considered  to be related  to the study  drug.  Applicable  forms 
provided  by the Sponsor  or their designee  must  be transmitted  via secure  e-mail within  24 
hours of discovery to pv_istari@klserv.com . 
 
All suspected adverse events that are both serious and unexpected should be reported 
immediately to the PI, Dr. Shelley Hwang, or her designee. Unexpected fatal or life - 
threatening suspec ted adverse  events will be  reported to the FDA by  telephone, facsimile, 
or in writing  as soon  as possible,  but no later than 7 calendar  days  after first knowledge  by 
the Sponsor or their designee followed by a complete report within 8 additional calendar 
days. Unexpected  adverse  events  that are both serious  and suspected,  but not fatal or life- 
threatening, will be reported to the FDA by telephone, facsimile, or in writing as soon as 
possible, but no later than 15 calendar days after first knowledge by the Sponsor or their 
designee.  
 
All adverse events that are considered serious, unanticip ated or unexpected, and related 
or possibly related to the research (as defined by 21CRF312.32[a]) will be reported to the 
Duke University Medical Center IRB using the appropriate Serious Adverse Event (SAE) 
report form within the following guidelines:  

 
 • Report  within  24 hours  of learning  about  any subject’s  death  that was unanticipated  and 
more likely related to the research than unrelated;  
• Report  within  5 business  days  of learning  about  any serious,  unanticipated,  and related 
or possibly/pr obably related adverse event;  
• Report within 10 business days of learning about any other unanticipated problem or 
event that was more likely related to the research than unrelated.  
 
At the time of the annual  report  to the FDA,  a summary  of the overall  toxicity  experience  will 
be provided.  
 
Safety  Oversight  Committee  
The Duke Cancer Institute Safety  Oversight Committee is responsible for annual data and 
safety monitoring of DUHS sponsor -investigator phase I and II therapeutic interventional 
studies that do not have an independent Data Safety Monitoring Board (DSMB). The 
primary  focus  of the Safety  Oversight  Committee  is the review  of safety  data,  toxicities  and 
new information that may affect subject safety or efficacy. Annual safety reviews incl ude 
but may not be limited to review of safety data, enrollment status, stopping rules if 
applicable,  accrual, toxicities,  reference  literature, and interim  analyses  as provided by  the 
Principal  Investigator.  The Safety  Oversight  Committee  in concert  with the DCI 
Monitoring Team ( Section 14.1 below) oversees the conduct of DUHS cancer -related, 
greater -than-minimal -risk intervention studies that do not have an external monitoring  
plan,  ensuring  subject  safety  and that the protocol  is conducted,  recorded  and reported  in 
accordance with the protocol, standing operating procedures (SOPs), Good Clinical 
Practice  (GCP),  and applicable regulatory requirements.  
 
External  Data  and Safety  Monitoring  
Dr. Elizabeth A. Mittendorf will serve as the research monitor for this protocol.  Per DoD 
3216.02, at a minimum, the research monitor may discuss the research protocol with the 
investigators,  interview  human  subjects,  and consult  with others  outside  of the study  about 
the research;  shall have  authority  to stop a research  protocol  in progress,  remove  individual 
human  subjects  from a research  protocol,  and take whatever  steps  are necessary  to protect 
the safety and well -being of human subjects until the IRB can assess the monitor's report; 
and sh all have the responsibility to promptly report their observations and findings to the 
IRB or other designated official and the Human Research Protection Office (HRPO). IND 
safety reports and other notable safety information from all ongoing PVSRIPO clinica l 
investigations will be provided to the PI by the Sponsor or their designee, who will then 
communicate  relevant  information  with Dr. Mittendorf  and the DoD,  per their communication 
plans.  
 
If the  PI or  DCI has  a potential  conflict  of interest with conduct  of this protocol,  the protocol 
may require additional oversight beyond or in place of the SOC in the form of an external 
DSMB. If a potential conflict of interest exists, the PI should contact the Duke Research 
Integrity  Office  (RIO)  to develop  a conflict  of interest  management  plan for the protocol.  The 
plan should  describe  who will comprise  the external  DSMB,  how frequently  it will meet,  what 
it will review, and the criteria it will use to determine whether it is safe to proceed with  the 
protocol.  Due to a  potential conflict of interest,  an external DSMB -Plus was created for the  

 
 original phase I clinical trial in adult patients with Grade IV malignant glioma performed by 
the Preston  Robert  Tisch  Brain  Tumor  Center  (PRTBTC)  at Duke  University  Medical  Center 
and was extended to all other studies with PVSRIPO conducted by the PRTBTC. As the 
current study is being supported by a grant from the DoD, which requires and provides 
independent medical monitoring, RIO has dete rmined that no additional oversight is 
required by an external DSMB.  
 
14 QUALITY  CONTROL  AND QUALITY  ASSURANCE  
Monitoring  
This clinical  research study  will be monitored  both internally  by the PI and institutionally  by 
the Duke  Cancer  Institute  (DCI)  and poss ibly by the Sponsor  or their designee.  In terms  of 
internal review, the PI will continuously monitor and tabulate adverse events.  Appropriate 
reporting to the Duke University Medical Center IRB will be made.  If an unexpected 
frequency of Grade III or IV events occur, depending on their nature, action appropriate to 
the nature  and frequency  of these  adverse  events  will be taken.  This may require  a protocol 
amendment,  dose  de-escalation,  or potentially  closure  of the study.  The PI of this study  will 
also continuously monitor the conduct, data, and safety of this study to ensure that:  
• If stopping  rules  for toxicity  are met, the study  will be halted;  
• Risk/benefit  ratio is not altered  to the detriment  of the subjects;  
• Appropriate  internal  monitoring  of AEs and outcomes  is done;  
• Over -accrual  does  not occur;  
• Under -accrual  is addressed  with appropriate  amendments  or actions;  
• Data  are being  appropriately  collected  in a reasonable  and timely  manner.  
 
The DCI Monitoring Team will conduct monitoring visits to ensure subject safety and to 
ensure that the protocol is conducted, recorded, and reported in accordance with the 
protocol, stan dard operating procedures, good clinical practice, and applicable regulatory 
requirements. DCI review and monitoring of this protocol occurs in accordance with the 
NCI-approved Data and Safety Monitoring Plan.  Briefly, protocol review begins with an 
initial review by the Cancer Protocol Committee (CPC), which assesses the ethics and 
safety of the protocol.  Documentation of these assessments will be maintained.  Formal, 
independent monitoring will be conducted by the DCI Monitoring Team after the first 3 
subjects are enrolled,  followed  by annual  monitoring  of 1-3 subjects  until the study  is closed 
to enrollment and subjects are no longer receiving study interventions that are more than 
minimal risk.  
 
DCI Monitoring  Team  reports  and additional  data/safety/toxicity  reports  submitted  by the PI 
will be reviewed by the Safety Oversight Committee on an annual basis.  Additional 
monitoring may be prompted by findings from monitoring visits, unexpected frequency of 
serious and/or unexpected toxicities, or other concerns.  Monitoring visits may also be 
initiated  upon  request  by DUHS  and DCI Leadership,  CPC,  Safety  Oversigh t Committee,  a 
sponsor, an investigator, or the IRB.  All study documents must be made available upon 
request to the DCI Monitoring Team and other  authorized regulatory  authorities, including, 
but not limited to the National Institute of Health, National Ca ncer Institute, and the FDA. 
Every reasonable effort will be made to maintain confidentiality during study monitoring.  

 
 Audits  
The Duke  School  of Medicine  Office  of Audit,  Risk,  and Compliance  (OARC)  office  and the 
Sponsor  or their designee  may conduct  confidential  audits  to evaluate  compliance  with the 
protocol and the principles of GCP. The PI agrees to allow the auditor(s) direct access to 
all relevant documents and to allocate his/her time and the time of the study team to the 
auditor(s) in order to discuss findings and any relevant issues.  
 
Audit s are designed  to protect  the rights  and well-being  of human  research  subjects.  OARC 
audits may be routine or directed. Routine audits are selected based upon risk metrics 
generally geared towards high subject enrollment, studies with limited oversight or 
monitoring,  investigator initiated  investigational drugs  or devices, federally -funded studies, 
high degree of risk (based upon adverse events, type of study, or vulnerable populations), 
phase I studies, or studies that involve Medicare populations. Directe d audits occur at the 
directive of the IRB or an authorized institutional official.  
 
OARC audits examine research studies/clinical trial methodology, processes and systems 
to assess whether the research is conducted according to the protocol approved by th e 
DUHS  IRB. The primary  purpose  of the audit/review  is to verify  that the standards  for safety 
of human subjects in clinical trials and the quality of data produced by the clinical trial 
research are met. The audit/review will serve as a quality assurance measure, internal to 
the institution.  Additional  goals  of such  audits  are to detect  both random  and systemic  errors 
occurring during the conduct of clinical research and to emphasize “best practices” in the 
research/clinical trials environment.  
 
Data  Management  and Processing  
14.3.1  Case  Report  Forms  (CRFs)  
The electronic CRF (eCRF) will be the primary data collection document for the study and 
is developed in conjunction with statistical  oversight. The CRFs will be updated in a timely 
manner following acquisition of new source data. Only the PI, the study coordinator, the 
data management team, and the clinical trials m anager are permitted to make entries, 
changes, or corrections in the eCRF.  
 
An audit trail will be maintained automatically by the electronic CRF  management system. 
All users of this system will complete user training, as required or appropriate per DCI 
requirements and other regulations.  
14.3.2  Data  Management  Procedures  and Data  Verification  
Access  to electronic  databases  will be managed  by the DCI IT staff.  
 
Completeness  of entered  data will be checked  automatically  by the eCRF  system  and users 
will be alerted to the presence of data inconsistencies. Additionally, the data manager  and 
the statistical team will cross -reference the data to verify accuracy. Missing or implausible 
data will be highlighted  for the PI requiring  appropriate  respon ses (i.e. confirmation  of data, 
correction of data, completion or confirmation that data is not available, etc.).  
 
The database  will be reviewed  and discussed  prior to database  closure,  and will be closed  

 
 only after resolution of all remaining queries.  An audit trail will be kept of all subsequent 
changes to the data.  
14.3.3  Study  Closure  
Following completion of the studies, the PI will be responsible for ensuring the following  
activities:  
- Data  clarification  and/o r resolution  
- Accounting,  reconciliation,  and destruction/return  of used  and unused  study  drugs  
- Review  of site study  records  for completeness  
- Shipment  of all remaining  laboratory  samples  to the designated  laboratories  
 
15 STATISTICAL  METHODS  AND DATA  ANALYSIS  
Six women with breast cancer will participate in this pilot clinical study. The study is 
designed as an exploratory pilot study only to assess PVSRIPO bioactivity. Any subjects 
who do not have evaluable tumor tissue from both the pre -treatment bio psy and post - 
treatment surgery will be replaced.  
 
Our primary objective is to describe the change in the amount of tumor infiltrating immune 
cells in tumor pre - and post-injection of PVSRIPO by H&E. Given the small sample size of 
this study, descriptive s tatistics will be used to summarize inflammatory and immune 
signatures in tumor and blood, tumor infiltrating immune cell analysis, changes in immune 
cell composition in blood and changes in T cell activation in blood. Some statistical 
comparisons may be c onducted in an exploratory manner.  
 
Tumor specimens collected pre and post injection of PVSRIPO will be examined for 
inflammatory and immune signature using arrays, tumor infiltrating cells by H&E and IHC, 
and CD155 expression by IHC. The level of the immu ne checkpoint PD -L1 expression in 
tumor tissue before and after PVSRIPO injection will also be examined. Mean changes in 
these  outcomes  will be computed,  and a paired  t-test or Wilcoxon  signed -rank test may be 
conducted with appropriate adjustment for mult iple comparison.  
 
Changes over time in inflammatory and immune signature using arrays, immune cell 
composition (antigen presenting cells, B cells and T cells) and T cell activation by flow 
cytometry  will be described.  Changes  over time in B cell activation  using  ELISA  and peptide 
arrays will be described. Measurements will be obtained on day -7 (range day -7 to -10, 
before  polio  vaccine  booster),  day 0 (before  PVSRIPO  injection),  day 2 (range  day 1-2 after 
PVSRIPO),  day 14 (range  day 10 to 20, after PVSRIPO  before  surgery)  and in follow -up at 
months 1 and 6 (after PVSRIPO).  
 
Additional  descriptive  analyses  besides  those described  here may be conducted using the 
samples collected.  
 
 
16 ADMINISTRATIVE  AND ETHICAL  CONSIDERATIONS  
Regulatory  and Ethical  Compliance  
This protocol was designed and will be conducted and reported in accordance with the 
International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for 
Good Clinical Practice, the Declaration of Helsinki,  and applicable federal, state, and local 
regulations.  
 
DUHS  Institutional  Review  Board  and DCI Cancer  Protocol 
Committee  
The protocol, informed consent form, advertising material, and additional protocol -related 
documents  will be submitted  to the DUHS  Institutional  Review  Board  (IRB)  and DCI Cancer 
Protocol Committee (CPC) for review. The study will be initiated only after the Principal 
Investigator has received written and dated approval from the CPC, IRB, and Sponsor 
representative or their designee.  
 
The Principal Investigator will submit and obtain approval from the IRB for all subsequent 
protocol  amendments  and changes  to the informed  consent  form.  The CPC  will be informed 
about  any protocol  amendments  that potentially  affect  research  design  or data analysis  (i.e. 
amendments  affecting  subject  population,  inclusion/exclusion  criteria,  agent  administration, 
statistical analysis, etc.).  
 
The Principal  Investigator will obtain protocol  re-approval  from the IRB within 1 year of the 
most  recent  IRB approval.  The Principal  Investigator  must  also obtain  protocol  re-approval 
from the CPC within 1 year of the most recent IRB approval, for as long as the protocol 
remains open to subject enrollment.  
 
Informed  Consent  
The informed  consent  form will be written  in a manner  that is understandable  to the subject 
population. Prior to its use, the informed consent form will be approved by the IRB.  
 
The Principal  Investigator  or authorized  key personnel  will discuss  with the potential  subject 
the purpose of th e research, methods, potential risks and benefits, subject concerns, and 
other study -related matters. This discussion will occur in a location that ensures subject 
privacy and in a manner that minimizes the possibility of coercion. Appropriate 
accommodatio ns will be made available for potential subjects who cannot read or 
understand English or  are visually impaired. Potential subjects will have the opportunity to 
contact the Principal Investigator or authorized key personnel with questions, and will be 
given as much time as needed to make an informed decision about participation in the 
study.  
 
Before conducting any study -specific procedures, the Principal Investigator must obtain 
written informed consent from the subject or a legally acceptable representativ e. The 
original informed consent form will be stored with the subject’s study records, and a copy 
of the informed consent form will be provided to the subject. The Principal Investigator is 
responsible  for asking  the subject  whether  the subject  wishes  to notify his/her  primary  care 

 
 physician about participation in the study. If the subject agrees to such notification, the 
Principal Investigator will inform the subject’s primary care physician about the subject’s 
participation in the clinical study.  
 
Study  Documentation  
Study documen tation includes, but is not limited to, source documents, case report forms 
(CRFs), monitoring logs, appointment schedules, study team correspondence with 
sponsors/their designees or regulatory bodies/committees, and regulatory documents that 
can be found in the DCI -mandated “Regulatory Binder,” which includes, but is not limited 
to, approved  protocols,  approved  informed  consent  forms,  FDA Forms  1572,  and laboratory 
certifications.  
 
Source  documents  are original  records  that contain source  data, which is  all information  in 
original records of clinical findings, observations, or other activities in a clinical trial 
necessary  for the reconstruction  and evaluation  of the trial. Source  documents  include,  but 
are not limited  to, hospital  records,  clinical  and office  charts,  laboratory  notes,  memoranda, 
subjects’  diaries  or evaluation  checklists,  pharmacy  dispensing  records,  recorded  data from 
automated  instruments,  copies  or transcriptions  certified  after verification  as being  accurate 
copies, microfiches, phot ographic negatives, microfilm or magnetic media, x -rays, subject 
files, and records kept at the pharmacy, at the laboratories and at medico -technical 
departments involved in the clinical trial. When possible, the original record should be 
retained  as the source  document.  However,  a photocopy  is acceptable  provided  that it is a 
clear, legible, and an exact duplication of the original document.  
 
An electronic database, specifically RAVE, will be the primary documentation for case 
report  forms  (CRFs)  in this study.  The CRFs  will be updated  within  two weeks  of acquisition 
of new source data. Only approved staff as indicated in the in key personnel l og, are 
permitted  to make  entries,  changes,  or corrections  in the CRF.  Changes  or corrections  will 
be dated, initialed, and explained (if necessary). The Principal Investigator or authorized 
key personnel will maintain a record of the changes and correctio ns. 
 
Privacy,  Confidentiality,  and Data  Storage  
The Principal  Investigator  will ensure  that subject  privacy  and confidentiality  of the subject’s 
data will be maintained. Research Data Security Plans (RDSPs) will be approved by the 
appropriate institutional Site Based Research group.  
 
To protect  privacy,  every  reasonable  effort  will be made  to prevent  undue  access  to subjects 
during  the course of the study.  Prospective  participants  will be consented  in an exam  room 
where it is just the research staff, the patient and his family, if desired. For all future visits, 
interactions with research staff (study doctor and study coordinators) regardi ng research 
activities will take place in a private exam room. All research related interactions with the 
participant will be conducted by qualified research staff who are directly involved in the 
conduct of the research study.  
 
To protect confidentiality,  subject files in paper format will be stored in secure cabinets 
under  lock and key accessible  only by the research  staff.  Subjects  will be identified  only by 
a unique  study  number  and subject  initials.  Electronic  records  of subject  data will be 

 
 maintained  using  a dedicated  21 CFR Part 11 compliant  database  (Medidata  RAVE),  which 
is housed in an encrypted and password -protected file on a secure network drive. Access 
to electronic databases will be limited to designated key personnel as indicated in the 
delegation log. Subject data may be stored temporarily on encrypted and pa ssword - 
protected portable memory devices such  as flash drives and external hard drives,  but only 
when absolutely necessary. Data stored on portable memory devices will be de -identified. 
Subject data will be deleted from the portable memory device at the e arliest opportunity. 
The security and viability of the IT infrastructure will be managed by the DCI and/or Duke 
Medicine.  
 
Upon completion of the study, research records will be archived and handled per DUHS 
HRPP policy. Subject names or identifiers will not be used in reports, presentations at 
scientific meetings, or publications in scientific journals.  
 
Data  and Safety  Moni toring  
Data  and Safety  Monitoring  will be performed  in accordance  with the DCI Data  and 
Safety  Monitoring  Plan.  For a more  detailed  description,  please  refer to Section  13.3 and 
14.1 in this protocol.  
 
Protocol  Amendments  
All protocol amendments must be initiated by the Principal Investigator and approved by 
the IRB and Sponsor prior to implementation. IRB approval is not required for protocol 
changes that occur to protect the safety of a subject from an immediate hazard. H owever, 
the Principal Investigator must inform the IRB and all other applicable regulatory agencies 
of such action immediately.  
 
Though  not yet required,  the CPC  should  be informed  about  any protocol  amendments  that 
potentially affect research design or da ta analysis (i.e. amendments affecting subject 
population, inclusion/exclusion criteria, agent administration, etc.).  
 
Records  Retention  
The Principal  Investigator  will maintain  study -related  records  for a period  of: 
- at least  two years  after the date on which  a New Drug  Application  is approved  by the FDA 
(if an IND is involved)  
- at least two years after formal withdrawal of the IND associated with this protocol (if an 
IND is involved)  
- at least  six years  after study  completion  (Duke  policy)  
 
17 REFERENCES  
1. in Atlanta,  GA. (American  Cancer  Society,  2015).  
2. C. A. Santa -Maria,  W. J. Gradishar,  Changing  Treatment  Paradigms  in Metastatic  Breast 
Cancer: Lessons Learned. JAMA Oncol 1, 528 -534; quiz 549 (2015).  
3. L. A. Newman, J. S. Reis -Filho, M. Morrow, L. A. Carey, T. A. King, The 2014 Society of 
Surgical  Oncology  Susan  G. Komen  for the Cure Symposium:  triple -negative  breast  cancer. 
Ann Surg Oncol 22, 874 -882 (2015).  

 
 4. J. Bernier,  P. M. Poortmans,  Surgery  and radiation  therapy  of triple -negative  breast  cancers: 
From biology to clinics. Breast 28, 148 -155 (2016).  
5. O. Hamid,  C. Robert,  A. Daud,  F. S. Hodi,  W. J. Hwu,  R. Kefford,  J. D. Wolchok,  P. Hersey,  
R. W. Joseph,  J. S. Weber,  R. Dronca,  T. C.  Gangadhar,  A. Patnaik,  H. Zarour,  A. M. Joshua,  
K. Gergich, J. Elassaiss -Schaap, A. Algazi, C. Mateus, P. Boasberg, P. C. Tumeh, B. 
Chmielowski,  S. W. Ebbinghaus,  X. N. Li, S. P. Kang,  A. Ribas,  Safety  and tumor  responses 
with lambrolizumab (anti -PD-1) in melanoma. N Engl J Med 369, 134 -144 (2013).  
6. M. Jia, W. Feng,  S. Kang,  Y. Zhang,  J. Shen,  J. He, L. Jiang,  W. Wang,  Z. Guo,  G. Peng,  G. 
Chen, J. He, W. Liang, Evaluation of the efficacy and safety of anti -PD-1 and anti -PD-L1 
antibody  in the treatment of  non-small  cell lung cancer  (NSCLC):  a meta -analysis.  J Thorac 
Dis 7, 455 -461 (2015).  
7. T. Y. Seiwert, B. Burtness, R. Mehra, J. Weiss, R.  Berger, J. P. Eder, K. Heath, T. 
McClanahan,  J. Lunceford,  C. Gause,  J. D. Cheng,  L. Q. Chow,  Safety  and clinical  activity  of 
pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head 
and neck  (KEYNOTE -012):  an open -label,  multicentre,  phase  1b trial. Lancet  Oncol  17, 956- 
965 (2016).  
8. J. E. Rosenberg,  J. Hoffman -Censits,  T. Powles,  M. S. van der Heijden,  A. V. Balar,  A. Necchi,  
N. Dawson,  P. H. O'Donnell,  A. Balmanoukian,  Y. Loriot,  S. Srinivas,  M. M. Retz,  P. Grivas,  
R. W. Joseph,  M. D. Galsky,  M. T. Fleming,  D. P. Petrylak,  J. L. Perez -Gracia,  H. A. Burris,  D. 
Castellano,  C. Canil,  J. Bellmunt,  D. Bajorin,  D. Nickles,  R. Bourgon,  G. M. Frampton,  N. Cui, 
S. Mariathasan, O. Abidoye, G. D. Fine, R. Dreicer, Atezolizuma b in patients with locally 
advanced and metastatic urothelial carcinoma who have progressed following treatment with 
platinum -based  chemotherapy:  a single -arm, multicentre,  phase  2 trial. Lancet  387, 1909 -1920 
(2016).  
9. R. Nanda,  L. Q. Chow,  E. C. Dees,  R. Berger,  S. Gupta,  R. Geva,  L. Pusztai,  K. Pathiraja,  G. 
Aktan, J. D. Cheng, V. Karantza, L. Buisseret, Pembrolizumab in Patients With Advanced 
Triple -Negative  Breast  Cancer:  Phase  Ib KEYNOTE -012 Study.  J Clin Oncol  34, 2460 -2467 
(2016).  
10. K. Muro,  H. C. Chung,  V. Shankaran,  R. Geva,  D. Catenacci,  S. Gupta,  J. P. Eder,  T. Golan,  D. 
T. Le, B. Burtness,  A. J. McRee,  C. C. Lin, K. Pathiraja,  J. Lunceford,  K. Emancipator,  J. Juco,  
M. Koshiji, Y. J. Bang, Pembrolizumab for patients with PD -L1-positive advanced gastric 
cancer  (KEYNOTE -012):  a multicentre,  open -label,  phase  1b trial. Lancet  Oncol  17, 717-726 
(2016).  
11. S. Dushyanthen,  P. A. Beavis,  P. Savas,  Z. L. Teo, C. Zhou,  M. Mansour,  P. K. Darcy,  S. Loi, 
Relevance of tumor -infiltrating lymphocytes in breast cancer. BMC Med 13, 202 (2015).  
12. B. F. Emens  LA, Cassier P,  et al., in Presented  at 2014  San Antonio  Breast  Cancer  Symposium  
(San Antonio,  Texas.,  December  9-13, 2014).  
13. E. Y. Dobrikova,  C. Goetz,  R. W. Walters,  S. K. Lawson,  J. O. Peggins,  K. Muszynski,  S. 
Ruppel, K. Poole, S. L. Giardina, E. M. Vela, J. E. Estep, M. Gromeier, Attenuation of 
neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after 
intrathalamic inoculation in Macaca fascicularis. J Virol 86, 2750 -2759 (2012).  
14. C. L. Mendelsohn,  E. Wimmer,  V. R. Racaniello,  Cellular  receptor  for poliovirus:  molecular 
cloning, nucleotide sequence, and expression of a new member of the immunoglobulin 
superfamily. Cell 56, 855 -865 (1989).  
15. Y. Takai,  J. Miyoshi,  W. Ikeda,  H. Ogita,  Nectins  and nectin -like molecules:  roles  in contact 
inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol 9, 603 -615 (2008).  
 
 16. K. E. Sloan,  B. K. Eustace,  J. K. Stewart,  C. Zehetmeier,  C. Torella,  M. Simeone,  J. E. Roy,  C. 
Unger, D. N. Louis, L. L. Ilag, D. G. Jay, CD155/PVR plays a key role in cell motility during 
tumor cell invasion and migration. BMC Cancer 4, 73 (2004).  
17. M. Gromeier,  S. Lachmann,  M. R. Rosenfeld,  P. H. Gutin,  E. Wimmer,  Intergeneric  poliovirus 
recombin ants for the treatment of malignant glioma. Proc Natl Acad Sci U S A 97, 6803 -6808 
(2000).  
18. H. Toyoda, J. Yin, S. Mueller, E. Wimmer, J. Cello, Oncolytic treatment and cure of 
neuroblastoma  by a novel  attenuated  poliovirus  in a novel  poliovirus -susceptible  animal  model. 
Cancer Res 67, 2857 -2864 (2007).  
19. J. M. Morrison,  V. R. Racaniello,  Proteinase  2Apro  is essential  for enterovirus  replication  in 
type I interferon -treated cells. J Virol 83, 4412 -4422 (2009).  
20. H. Ochiai, S. A. Moore, G. E. Archer, T. Okamura, T. A. Chewning, J. R. Marks, J. H. 
Sampson, M. Gromeier, Treatment of intracerebra l neoplasia and neoplastic meningitis with 
regional  delivery  of oncolytic  recombinant  poliovirus.  Clin Cancer  Res 10, 4831 -4838  (2004).  
21. V. Chandramohan,  J. D. Bryant,  H. Piao,  S. T. Keir,  E. S. Lipp,  M. Lefaivre,  K. Perkinson,  D. 
D. Bigner,  M. Gromeier,  R. E. McLendon,  Validation  of an Immunohistochemistry  Assay  for 
Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Arch Pathol Lab Med , 
(2017).  
22. M. I. Dobrikov,  E. Y. Dobrikova,  M. Gromeier,  Dynamic  regulation  of the translation  initiation 
helicase  complex  by mitogenic  signal  transduction  to eukaryotic  translation  initiation  factor  4G. 
Mol Cell Biol 33, 937 -946 (2013).  
23. M. Dobrikov, E. Dobrikova, M. Shveygert, M. Gromeier, Phosphorylation of eukaryotic 
translation  initiation  factor  4G1 (eIF4G1)  by protein  kinase  C{alpha}  regulates  eIF4G1  binding 
to Mnk1. Mol Cell Biol 31, 2947 -2959 (2011).  
24. C. Goetz,  R. G. Everson,  L. C. Zhang,  M. Gromeier,  MAPK  signal -integrating  kinase  controls 
cap-independent translation and cell type -specific cytotoxicity of  an oncolytic  poliovirus. Mol 
Ther 18, 1937 -1946 (2010).  
25. A. Astanehe,  M. R. Finkbeiner,  M. Krzywinski,  A. Fotovati,  J. Dhillon,  I. M. Berquin,  G. B. 
Mills, M. A. Marra, S. E. Dunn, MKNK1 is a YB -1 target gene responsible for imparting 
trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 31, 4434 -4446 
(2012).  
26. D. Etchison, S. C. Milburn, I. Edery, N. Sonenberg, J. W. Hershey, Inhibition of HeLa cell 
protein  synthesis  following  poliovirus  infection  correlates  with the proteolysis  of a 220,000 - 
dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein 
complex. J Biol Chem 257, 14806 -14810 (1982).  
27. M. C. Brown,  E. K. Holl,  D. Boczkowski,  E. Dobrikova,  M. Mosaheb,  V. Chandramohan,  D. 
D. Bigner, M. Gromeier, S. K. Nair, Cancer immunotherapy with recombinant poliovirus 
induces  IFN-dominant  activation  of dendritic  cells and tumor  antigen -specific  CTLs.  Sci Transl 
Med 9, (2017).  
28. G. Kroemer,  L. Galluzzi,  O. Kepp,  L. Zitvogel,  Immunogenic  cell death  in cancer  therapy.  
Annu  Rev Immunol 31, 51-72 (2013).  
29. R. Wahid,  M. J. Cannon,  M. Chow,  Dendritic  cells and macrophages  are productively  infected 
by poliovirus. J Virol 79, 401 -409 (2005).  
30. E. Y. Dobrikova,  T. Broadt,  J. Poiley -Nelson,  X. Yang,  G. Soman,  S. Giardina,  R. Harris,  M. 
Gromeier, Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic 
adaptation to a pathogenic phenotype. Mol Ther 16, 1865 -1872 (2008).  
 
 31. H. Ochiai, S. A. Campbell, G. E. Archer, T. A. Chewning, E. Dragunsky, A. Ivanov, M. 
Gromeier,  J. H. Sampson,  Targeted  therapy  for glioblastoma  multiforme  neoplastic  meningitis 
with intrathecal delivery of an oncolytic recombinant poliovirus. Clin Cancer Res 12, 1349 - 
1354 (2006).  
32. H. Toyoda, E. Wimmer, J. Cello, Oncolytic poliovirus therapy and immunization with 
poliovirus -infected  cell lysate  induces  potent  antitumor  immunity  against  neuroblastoma  in 
vivo. Int J Oncol 38, 81-87 (2011).  
33. H. H. Ho, L. B. Ivashkiv,  Role  of STAT3  in type I interferon  responses.  Negative  regulation  of 
STAT1 -dependent inflammatory gene activation. J Biol Chem 281, 14111 -14118 (2006).  
34. S. K. Pr uitt, D. Boczkowski, N. de  Rosa, N. R. Haley, M. A. Morse, D. S. Tyler, J. Dannull, S. 
Nair,  Enhancement  of anti-tumor  immunity  through  local  modulation  of CTLA -4 and GITR  by 
dendritic cells. Eur J Immunol 41, 3553 -3563 (2011).  
35. M. Gromeier,  L. Alexander,  E. Wimmer,  Internal  ribosomal  entry  site substitution  eliminates 
neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A 93, 2370 - 
2375 (1996).  
36. M. C. Brown,  E. Y. Dobrikova,  M. I. Dobrikov,  R. W. Walton,  S. L. Gemberling,  S. K. Nair,  
A. Desjardins,  J. H. Sampson,  H. S. Friedman,  A. H. Friedman,  D. S. Tyler,  D. D. Bigner,  M. 
Gromeier, Oncolytic polio virotherapy of cancer. Cancer 120, 3277 -3286 (2014).  